




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07C 323/10, C07D 249/10, 239/32, 213/62, A61K 31/095, 31/4196, 31/505, 31/4402, A61P 25/04, 29/00</p>	A1	<p>(11) International Publication Number: WO 00/37438</p> <p>(43) International Publication Date: 29 June 2000 (29.06.00)</p>		
<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/SE99/02401</p> <p>(22) International Filing Date: 17 December 1999 (17.12.99)</p> <p>(30) Priority Data: <div style="display: flex; justify-content: space-between; margin-top: 5px;"> 9804493-6 22 December 1998 (22.12.98) SE 60/113,542 22 December 1998 (22.12.98) US </div> </p> <p>(71) Applicant (for all designated States except MG US): ASTRA PHARMA INC. [CA/CA]; 1004 Middlegate Road, Mississauga, Ontario L4Y 1M4 (CA).</p> <p>(71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): DIXIT, Dilip [CA/CA]; 72 Jean Brillant, Roxboro, Quebec H8Y 2S5 (CA). BEDNARSKI, Krzysztof [CA/CA]; 237 Labrie, Laval, Quebec H7N 5R6 (CA). LI, Tiechao [CA/US]; 12853 Turnham Drive, Fishers, IN 46038 (US). ROBERTS, Edward [GB/CH]; Höhenweg 12, CH-4112 Flüh (CH). STORER, Richard [GB/CA]; 215 Oakridge, Baie d'Urfe, Quebec H9X 2N3 (CA). WANG, Wuyi [CA/CA]; 2297 Frenette, Ville St-Laurent, Quebec H4R 1M3 (CA).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/SE99/02401</p> <p>(22) International Filing Date: 17 December 1999 (17.12.99)</p> <p>(30) Priority Data: <div style="display: flex; justify-content: space-between; margin-top: 5px;"> 9804493-6 22 December 1998 (22.12.98) SE 60/113,542 22 December 1998 (22.12.98) US </div> </p> <p>(71) Applicant (for all designated States except MG US): ASTRA PHARMA INC. [CA/CA]; 1004 Middlegate Road, Mississauga, Ontario L4Y 1M4 (CA).</p> <p>(71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): DIXIT, Dilip [CA/CA]; 72 Jean Brillant, Roxboro, Quebec H8Y 2S5 (CA). BEDNARSKI, Krzysztof [CA/CA]; 237 Labrie, Laval, Quebec H7N 5R6 (CA). LI, Tiechao [CA/US]; 12853 Turnham Drive, Fishers, IN 46038 (US). ROBERTS, Edward [GB/CH]; Höhenweg 12, CH-4112 Flüh (CH). STORER, Richard [GB/CA]; 215 Oakridge, Baie d'Urfe, Quebec H9X 2N3 (CA). WANG, Wuyi [CA/CA]; 2297 Frenette, Ville St-Laurent, Quebec H4R 1M3 (CA).</p>	<p>(74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(21) International Application Number: PCT/SE99/02401</p> <p>(22) International Filing Date: 17 December 1999 (17.12.99)</p> <p>(30) Priority Data: <div style="display: flex; justify-content: space-between; margin-top: 5px;"> 9804493-6 22 December 1998 (22.12.98) SE 60/113,542 22 December 1998 (22.12.98) US </div> </p> <p>(71) Applicant (for all designated States except MG US): ASTRA PHARMA INC. [CA/CA]; 1004 Middlegate Road, Mississauga, Ontario L4Y 1M4 (CA).</p> <p>(71) Applicant (for MG only): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): DIXIT, Dilip [CA/CA]; 72 Jean Brillant, Roxboro, Quebec H8Y 2S5 (CA). BEDNARSKI, Krzysztof [CA/CA]; 237 Labrie, Laval, Quebec H7N 5R6 (CA). LI, Tiechao [CA/US]; 12853 Turnham Drive, Fishers, IN 46038 (US). ROBERTS, Edward [GB/CH]; Höhenweg 12, CH-4112 Flüh (CH). STORER, Richard [GB/CA]; 215 Oakridge, Baie d'Urfe, Quebec H9X 2N3 (CA). WANG, Wuyi [CA/CA]; 2297 Frenette, Ville St-Laurent, Quebec H4R 1M3 (CA).</p>	<p>(74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
<p>(54) Title: NOVEL THIO-AMINOTETRALIN COMPOUNDS USEFUL IN PAIN MANAGEMENT</p> <div style="text-align: center; margin: 20px 0;">  <p style="margin-top: 10px;">(I)</p> </div> <p>(57) Abstract</p> <p>The present invention relates to novel thio-aminotetralin compounds of formula (I) wherein Z, X, R₁, R₂, R₃, R₄, R₅, and R₆ are defined herein. The compounds are useful in pain management.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

NOVEL THIO-AMINOTETRALIN COMPOUNDS USEFUL IN PAIN MANAGEMENT

FIELD OF THE INVENTION

5 The present invention is related to compounds that exhibit analgesic activity and in particular compounds exhibiting analgesia due to their opioid receptor affinity.

BACKGROUND OF THE INVENTION

10 Many natural alkaloids and related analogs bind to specific opioid receptors and elicit an analgesic response similar to classic narcotic opiates. Many different types of opioid receptors have been shown to coexist in higher animals. For example, see W. Martin *et al.*, J. Pharmacol. Exp. Ther., 197, p. 517 (1975) ; and J. Lord *et al.*, Nature (London), 257, p.495 (1977). Three different types of opioid receptors have been identified. The first, δ ,
15 shows a differentiating affinity for enkephalin-like peptides. The second, μ , shows enhanced selectivity for morphine and other polycyclic alkaloids. The third, κ , exhibits equal affinity for either group of the above ligands and preferential affinity for dynorphin. In general, the μ receptors seem to be more involved with analgesic effects. The δ receptors appear to deal with behavioral effects, although the δ and the
20 κ receptors may also mediate analgesia.

Each opioid receptor, when coupled with an opiate, causes a specific biological response unique to that type of receptor. When an opiate activates more than one receptor, the biological response for each receptor is affected, thereby producing side effects. The less
25 specific and selective an opiate may be, the greater the chance of causing increased side effects by the administration of the opiate.


Opiates can cause serious and potentially fatal side effects. Side effects such as respiratory depression, tolerance, physical dependence capacity, and precipitated withdrawal syndrome
30 are caused by nonspecific interactions with central nervous system receptors. See K. Budd,

In International Encyclopedia of Pharmacology and Therapeutics ; N.E. Williams and H. Wilkinson, Eds., Pergammon : (Oxford), 112, p.51 (1983). It is therefore an object of the present invention to provide compounds having analgesic effects but having as few side-effects as possible.

5

DESCRIPTION OF THE INVENTION

In one aspect, the present invention provides novel thio aminotetralin compounds
10 represented by formula (I):



and pharmaceutically acceptable derivatives thereof;
wherein;

15 Z is S, SO or SO₂,

X is selected from any one of

(i) a bond;

(ii) -CR₇R₈- wherein R₇ and R₈ are independently selected from the group

consisting of H, OH, halogen, CN, COOH, CONH₂, amino, nitro, SH, C₁₋₆
20 alkyl where one or more of the carbon atoms may optionally be substituted by
one or more heteroatoms selected from O, S and N, C₂₋₆alkenyl where one or
more of the carbon atoms may optionally be substituted by one or more
heteroatoms selected from O, S and N, C₂₋₆alkynyl where one or more of the
carbon atoms may optionally be substituted by one or more heteroatoms
25 selected from O, S and N; and COOR_c wherein R_c is C₁₋₆alkyl, C₂₋₆alkenyl or
C₂₋₆alkynyl; R₇ and R₈ can also be connected to form C₃₋₈ cycloalkyl, a C₃₋₈
cycloalkenyl or a saturated heterocycle of from 3 to 8 atoms;

R₁ is selected from the group consisting of H, C₁₋₁₂alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₁₂alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₁₂alkynyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₆₋₁₂ aryl, C₆₋₁₂ aralkyl, C₆₋₁₂ aryloxy, C₁₋₁₂ acyl, heteroaryl having from 6 to 12 atoms, and phosphoryl;

R₂ and **R₃** are independently selected from the group consisting of C₁₋₆ alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkynyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₆₋₁₂ aryl, C₆₋₁₂ aralkyl, heteroaryl having from 6 to 12 atoms, and H; *or*

R₂ and **R₃** may together form a saturated heterocycle of from 3 to 8 atoms;

R₄ and **R₅** are independently selected from the group consisting of C₁₋₆ alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkynyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, and H;

R₄ and **R₅** can also be connected to form C₃₋₈ cycloalkyl, a C₃₋₈ cycloalkenyl or a saturated heterocycle of from 3 to 8 atoms;

R₆ is hydrogen, OH, C₁₋₆ alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkynyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, O-C₁₋₆ alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, O-C₂₋₆alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, O-C₂₋₆alkynyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, halogen, CN, COOH, CONH₂, amino, nitro, or SH;

with the provisos that:

- 1) not both **R₄** and **R₅** are H; and
- 2) at least one of **R₂** and **R₃** is H or C₁₋₆ alkyl.

The compounds of the present invention are useful in therapy, in particular as analgesics.

In another aspect, there is provided a method of treating pain in a mammal, comprising administering to said mammal an analgesic amount of a compound or composition of the invention.

- 5 Still another aspect of the invention is the use of a compound according to formula (I), for the manufacture of a medicament for the treatment of pain.

In another aspect, there is provided pharmaceutical compositions comprising compounds of the present invention and pharmaceutically acceptable carriers, diluents or adjuvants.

10

X is preferably $-\text{CR}_7\text{R}_8-$ wherein R_7 and R_8 are independently selected from the group consisting of OH, halogen, CN, COOH, CONH_2 , amino, nitro, SH, C_{1-6} alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, H, and COOR_c wherein R_c is C_{1-6} alkyl; R_7 and R_8 can also be
15 connected to form a C_{3-8} cycloalkyl.

X is more preferably $-\text{CR}_7\text{R}_8-$ wherein R_7 and R_8 are independently selected from the group consisting of C_{1-6} alkyl, and H.


X is most preferably $-\text{CH}_2-$.

- 20 R_1 is preferably selected from the group consisting of H, C_{1-12} alkyl, C_{6-12} aryl, and C_{6-12} aralkyl.

R_1 is more preferably selected from the group consisting of C_{1-6} alkyl, C_{6-12} aryl, and C_{6-12} aralkyl.

R_1 is most preferably C_{1-6} alkyl.

25




R_1 can also be , wherein n is an integer between 1 to 5, R_x and R_{x_1} are independently H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl. More preferably, n is 1 or 2 and R_x and R_{x_1} are C_{1-6} alkyl. Most preferably, R_x and R_{x_1} are methyl or ethyl.

In an alternative embodiment, R_1 is selected from the group consisting of CH_3 , $-(CH_2)_n-CH_3$, and $-(CH_2)_n-O-CH_3$ wherein n is an integer selected between 1 and 5.

In an alternative preferred embodiment R_1 is C_{6-12} aryl or heteroaryl having from 6 to 12 atoms.

In a further preferred embodiment, R_1 is selected from the group consisting of




wherein A is selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkyl, C_{2-6} alkenyl,

C_{2-6} alkynyl, $O-C_{1-6}$ alkyl, $O-C_{2-6}$ alkenyl, $O-C_{2-6}$ alkynyl, , $S-C_{1-6}$ alkyl, $S-C_{2-6}$ alkenyl,

$S-C_{2-6}$ alkynyl, $N-C_{1-6}$ alkyl, $N-C_{2-6}$ alkenyl, $N-C_{2-6}$ alkynyl, CF_3 , fluoro, chloro, bromo, iodo, OH, SH, CN, nitro, amino, aminoamidino, amidino, guanido, $COOH$, and $COOR_z$ wherein R_z is C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl.

In an alternative embodiment, R_1 is C_{6-12} aralkyl or heteroaryl having from 6 to 12 atoms.


More preferably, R_1 is selected from the group consisting of



wherein A is selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkyl, C_{2-6} alkenyl,

C_{2-6} alkynyl, $O-C_{1-6}$ alkyl, $O-C_{2-6}$ alkenyl, $O-C_{2-6}$ alkynyl, , $S-C_{1-6}$ alkyl, $S-C_{2-6}$ alkenyl,

$S-C_{2-6}$ alkynyl, $N-C_{1-6}$ alkyl, $N-C_{2-6}$ alkenyl, $N-C_{2-6}$ alkynyl, CF_3 , fluoro, chloro, bromo, iodo, OH, SH, CN, nitro, amino, aminoamidino, amidino, guanido, $COOH$, and $COOR_z$ wherein R_z is C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl and Y is $-(CH_2)_m-$ wherein m is an integer selected between 1 and 5.



R_1 is preferably or wherein A and Y are as defined above.

A is preferably selected from the group consisting of C_{1-6} alkyl, $O-C_{1-6}$ alkyl,

$S-C_{1-6}$ alkyl, OH, nitro, amino, aminoamidino, amidino, guanido, $COOH$, and $COOR_a$

wherein R_a is C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl. A is more preferably selected from the

5 group consisting of C_{1-6} alkyl, OH, nitro, amino, aminoamidino, amidino, guanido, and

$COOH$. A is most preferably selected from the group consisting of amidino, guanido, and OH.

R_2 and R_3 are preferably H.

10 R_4 and R_5 are preferably C_{1-4} alkyl substituted by a hydroxyl.

R_4 and R_5 are preferably C_{1-4} alkyl.


In a further preferred embodiment, R_4 and R_5 are independently selected from the group consisting of methyl, ethyl, isopropyl, propyl, butyl, and isobutyl.

R_4 and R_5 are preferably ethyl.


15 R_4 and R_5 are preferably methyl.

R_6 can be substituted at any position on the aromatic ring. More preferably R_6 is adjacent to the carbon bearing the OH. In an alternative embodiment, the present invention provides compounds of the formula (II) or (III)

20



(II)



(III)

and pharmaceutically acceptable derivative;

25 wherein each of X, Z, R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 are defined above.

R_6 is preferably, H, methyl, halogen or OR_b wherein R_b is C_{1-6} alkyl, C_{1-6} alkenyl or C_{1-6} alkynyl.

R_6 is most preferably H.

- 5 The compounds of the present invention contains at least 2 chiral centers which are marked by an asterik (*) on the general formula (I). The compounds of formula (I) thus exist in the form of different geometric(i.e. *trans* and *cis*) and optical isomers (i.e. (+) or (-) enantiomers). When there is 2 chiral centers at the position marked by the asteriks, the compounds may therefore be in the form of *cis* isomers or *trans* isomers. Each *cis* or *trans* isomers also exists as a (+) and (-) enantiomer. All such isomers, enantiomers and mixtures thereof including racemic mixtures are included within the scope of the invention.

Preferably the compounds of the present invention are in the form of the *trans* isomers.

- More preferably the compounds of the present invention are present in the form of *trans* (+) and *trans* (-) enantiomers.

Preferred compounds of the invention include: Trans-7-Amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol

(**compound #1**); Cis-7-Amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol

- 20 (**compound #2**); Trans-7-Amino-8,8-diethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol

(**compound #3**); Trans-7-Amino-8,8-dimethyl-6-phenylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-

ol (**compound #4**);

- 25 Trans-7-Amino-8,8-dimethyl-6-(pyridin-2-ylsulfanyl)-5,6,7,8-tetrahydro- naphthalen-2-ol (**Compound #5**);

Trans-7-Amino-8,8-dimethyl-6-(pyrimidin-2-ylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #6**);

- 30 Trans-7-Amino-6-(3-amino-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #7**);

Trans-7-Amino-8,8-dimethyl-6-(4-methylsulfanyl-phenylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #8**);

Trans-7-Amino-6-benzenesulfonylmethylsulfanyl-8,8-diethyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #9**);

5 Trans-2-(3-Amino-4,4-diethyl-6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-acetamide (**Compound #10**);

Trans-(3-Amino-4,4-diethyl-6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanylmethyl)-phosphonic acid diethyl ester (**Compound #11**);

10 Trans-7-Amino-8,8-diethyl-6-(2-hydroxy-ethylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #12**);

Trans-7-Amino-6-(5-amino-2*H*-[1,2,4]triazol-3-ylsulfanyl)-8,8-diethyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #13**);

Trans-7-Amino-6-(2-amino-ethylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #14**);

15 Trans-7-Amino-6-(5-amino-2*H*-[1,2,4]triazol-3-ylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #15**);

Trans-7-Amino-8,8-dimethyl-6-propylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #16**);

20 Trans-7-Amino-6-isopropylsulfanyl-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #17**);

Trans-7-Amino-6-(2-hydroxy-ethylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #18**);

Trans-2-(3-Amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-acetamide (**Compound #19**);

25 Trans-7-Dimethylamino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #20**);

8,8-dimethyl-trans-7-methylamino-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #21**);

30 Trans-7-Amino-8,8-diethyl-6-phenylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #22**);

8,8-dimethyl-trans-6-phenylsulfanyl-7-propylamino-5,6,7,8-tetrahydro-naphthalen-2-ol
(**Compound #23**);

Trans-7-Amino-6-(2-amino-phenylsulfanyl)-8,8-diethyl-5,6,7,8-tetrahydro-naphthalen-2-ol
(**Compound #24**;

5 Trans-7-Amino-8,8-dimethyl-6-(2,2,2-trifluoro-ethylsulfanyl)-5,6,7,8-tetrahydro-
naphthalen-2-ol (**Compound #25**);

Trans-4-(3-Amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-
butyric acid ethyl ester (**Compound #26**);

10 Trans-7-Amino-6-benzenesulfonylmethylsulfanyl-8,8-dimethyl-5,6,7,8-tetrahydro-
naphthalen-2-ol (**Compound #27**);

Trans-7-Amino-8,8-dimethyl-6-(3-phenyl-allylsulfanyl)-5,6,7,8-tetrahydro- naphthalen-2-
ol (**Compound #28**);

Trans-7-Amino-6-isobutylsulfanyl-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol
(**Compound #29**);

15 Trans-7-Amino-8,8-dimethyl-6-(2-phenoxy-ethylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-
ol (**Compound #30**);

Trans-7-Amino-8,8-diethyl-6-(2-phenoxy-ethylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol
(**Compound #31**);

(-)Trans-7-amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol
20 (**Compound #32**);

(+)Trans-7-amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol
(**Compound #33**); Trans-7-amino-6-(4-bromo-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-
tetrahydronaphthalen-2-ol (**Compound #34**);

Trans-7-amino-8,8-dimethyl-6-(naphthalen-2-ylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-
25 ol (**Compound #35**); Trans-7-Amino-6-(4-hydroxy-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-
tetrahydro-naphthalen-2-ol (**Compound #36**); Trans-7-amino-6-(4-amino-phenylsulfanyl)-
8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #37**); Trans-7-amino-6-(3-
hydroxy-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound**
#38); Trans-3-(3-Amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-
30 ylsulfanyl)-propionic acid ethyl ester (**Compound #39**); Trans-7-amino-8,8-dimethyl-6-

phenethylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol (**Compound #40**); Trans-2-(3-amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-2-ylsulfanyl)-propionamide (**Compound #41**); Trans-3-(3-amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-propionic acid (**Compound #42**); Trans-2-[3-(3-Amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-propionylamino]-3-(4-hydroxy-phenyl)-propionamide (**Compound #43**);
3-trans-(2-ethoxycarbonyl-ethylsulfanyl)-1,1-diethyl-7-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl (**Compound #44**);
3-trans-(2-carboxy-ethylsulfanyl)-1,1-diethyl-7-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl (**Compound #45**);

and pharmaceutically acceptable derivatives thereof; wherein said compound is in the form of the (+) enantiomer, the (-) enantiomer and mixture of the (+) and (-) enantiomer including racemic mixture.

15

More preferably the compound of the present invention is selected from the group consisting of **compound#1, compound#3, compound#4, compound#5, compound#9, compound#11, compound#15, compound#31, compound#32, compound#33, compound#36, compound#37, compound#39 compound#41, compound#43, compound #44 and compound #45.**

20

Most preferably the compound of the present invention is selected from the group consisting of **compound#1, compound#3, compound#5, compound#32, compound#33, compound#36, compound #44 and compound #45.**

25

As used in the present application the term "pain" represents "an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. The term "pain" also includes "acute pain" and chronic pain.

Acute pain is usually immediate and of a short duration. Acute pain can be present further to an injury, short-term illness, or surgical/medical procedure.

5 Examples of acute pain include a burn, a fracture, an overused muscle, or pain after surgery. Cancer pain may be long-lasting but acute due to ongoing tissue damage.

Some chronic pain is due to damage or injury to nerve fibers themselves (neuropathic pain).

10 Chronic pain can result from diseases, such as shingles and diabetes, or from trauma, surgery or amputation (phantom pain). It can also occur without a known injury or disease.

The present invention is directed to the treatment of all type of pain, including acute and chronic pain.

15

As used in this application, the term "**alkyl**" represents an unsubstituted or substituted (by a halogen, nitro, aminoamidino, amidino, guanido, CONH₂, COOH, O-C₁₋₆ alkyl, O-C₂₋₆ alkenyl, O-C₂₋₆ alkynyl, amino, hydroxyl or COOQ, wherein Q is C₁₋₆ alkyl, C₂₋₆ alkenyl, a C₂₋₆ alkynyl) straight chain, branched chain, or cyclic hydrocarbon moiety (e.g. isopropyl, ethyl, fluorethyl or cyclopropyl). The term alkyl is also meant to include
20 alkyls in which one or more hydrogen atoms is replaced by an halogen, more preferably, the halogen is fluoro (e.g., CF₃-, or CF₃CH₂-).

The term "**saturated heterocycle**" represents a carbocyclic ring in which one or more of
25 the from 3 to 8 atoms of the ring are elements other than carbon, such as N, S and O;

The term "**aryl**" represents an aromatic ring having from 6 to 12 carbon atoms, which may be substituted by a C₁₋₆ alkyl, C₂₋₆ alkenyl, a C₂₋₆ alkynyl, halogen, nitro, aminoamidino, amidino, guanido, CONH₂, COOH, O-C₁₋₆ alkyl, O-C₂₋₆ alkenyl, O-C₂₋₆ alkynyl, amino,

hydroxyl or COOQ, wherein Q is C₁₋₆ alkyl, C₂₋₆ alkenyl, a C₂₋₆ alkynyl, such as phenyl and naphthyl.

The term "**aralkyl**" represents an aryl group attached to the adjacent atom by a C₁₋₆alkyl,
5 C₁₋₆alkenyl, or C₁₋₆alkynyl(e.g., benzyl).

The term "**aryloxy**" represents an aryl or aralkyl moiety covalently bonded through an oxygen atom (e.g., phenoxy).

10 The term "**heteroaryl**" represents an aromatic ring in which one or more of the from 6 to 12 atoms in the ring are elements other than carbon, such as O, N, and S (e.g pyridine, isoquinoline, or benzothiophene).

The term "**acyl**" refers to a radical derived from a carboxylic acid, substituted (by
15 halogen(F, Cl, Br, I), C₆₋₂₀ aryl or C₁₋₆ alkyl) or unsubstituted, by replacement of the OH group. Like the acid to which it is related, an acyl radical may be aliphatic or aromatic, substituted (by halogen, C₁₋₅ alkoxyalkyl, nitro or OH) or unsubstituted, and whatever the structure of the rest of the molecule may be, the properties of the functional group remain essentially the same (e.g., acetyl, propionyl, isobutanoyl, pivaloyl, hexanoyl,
20 trifluoroacetyl, chloroacetyl, and cyclohexanoyl).

The term "**phosphoryl**" represents a radical derived from a phosphono moiety in which the hydrogen atom of at least one of the -OH can be replaced by C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆heteroalkyl, C₆₋₁₂ aryl, C₆₋₁₂ aralkyl, and C₆₋₁₂ heteroaryl(e.g.,
25 diethoxyphosphorylmethyl).

The term "**halogen**" encompasses chloro, fluoro, bromo and iodo;

In the present application the following abbreviations are used:


AcOEt ethyl acetate

Boc	t-butyloxycarbonyl
DMAP	4-dimethylaminopyridine
DME	ethylene glycol dimethylether
DMF	dimethylformamide
Et ₂ O	ether
Hex	hexane
HPLC	high performance liquid chromatography
LAH	lithium aluminium hydride
LHMDS	lithium bis(trimethylsilyl)amide
NHMDS	sodium bis(trimethylsilyl)amide
Ph	phenyl
PPTS	pyridium <i>p</i> -toluenesulfonate
PTSA	<i>p</i> -toluenesulfonic acid
r.t.	room temperature
sat.	saturated
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TLC	thin layer chromatography

When there is a sulfur atom present, the sulfur atom can be at different oxydation level, S, SO, or SO₂. All such oxydation level are within the scope of the present invention.

- 5 In yet another aspect of the invention, there is provided a process for preparing compounds of formula (I). The process is described in scheme 1 wherein each of X, R₁, R₂, R₃, R₄, R₅ and R₆ are as defined above and P, P1, P2, and P3 are protecting groups. If desired, the sulfur of the compound of formula Ia can be oxydized to S=O or SO₂ by methods well known in the art.

SCHEME 1

Step 1

The starting ketone AA was dissolved in a suitable solvent such as DMF, acetonitrile, THF, DME and was treated with sodium hydride or any other base such as potassium t-butoxide, sodium bis(trimethylsilyl)amide. The resulting mixture was then treated with ethyl iodide or any other alkyl halide such as methyl iodide, allyl bromide, diiodobutane to produce the compound A.

Step 2

The compound **A** was dissolved in a suitable solvent such as pyridine, DMF, ethanol and was treated with hydroxylamine hydrochloride or any other hydroxylamine salt such as
5 hydroxylamine sulfate, hydroxylamine bromide to produce the compound **B**.

Step 3

The compound **B** was dissolved in a suitable solvent as THF, dioxane, DME, and was
10 treated with LAH or any other reducing agent such as red-Al in presence of diethylamine or any other amine such as methylbutylamine, dipropylamine. The mixture was then heated to 50°C or at any higher temperature to produce the compound **C**.

Step 4

15

The compound **C** in was dissolved in a suitable solvent as dichloromethane (CH_2Cl_2) or in any other solvent such as dichloroethane, and was treated with BBr_3 or any other demethylating agent such as BCl_3 , HBr , to produce the compound **D**.

Step 5

The amino or hydroxyl groups of the compound **D** were protected with Boc or with any other protecting group, to produce the compound **E**. Protective groups are described in
25 Protective Groups in Organic Synthesis, 2nd ed., Greene and Wuts, John Wiley & Sons, New York, 1991 which is herein incorporated by reference.

Step 6

The compound E was dissolved in a suitable solvent such as ethanol or in any other alcohol
5 such as methanol, propanol, butanol and was treated with pyridinium p-toluenesulfonate
(PPTS) or any other acid or Lewis acid such as HCl, $\text{BF}_3 \cdot \text{OEt}_2$, PTSA, to produce the
compound F. Alternatively, a non alcoholic solvent can be used in combination with an
appropriate amount of an alcohol and a suitable Lewis acid such as ytterbium triflate see
for example *Tetrahedron Letters*, Vol. 37, No.43, pp7717-7720, 1996 which is herein
10 incorporated by reference.

Step 7

The protecting groups of the compound F were removed under appropriate conditions e.g.
15 with TFA or with any other acid such as HCl, PTSA, to produce the compound Ia.

It will be appreciated that certain substituents require protection during the course of the
synthesis and subsequent deprotection. For example, it may be necessary to protect an
hydroxyl group by conversion to an alkoxy or an ester and subsequently deprotected.
20 Protective groups for other substituents are described in Protective Groups in Organic
Synthesis, 2nd ed., Greene and Wuts, John Wiley & Sons, New York, 1991.

In another aspect, there is provided a method of agonizing or activating opioid receptors in
a mammal comprising administering to said mammal an opioid receptor agonizing or
25 activating amount of a compound or composition of the invention.

There is also provided pharmaceutically acceptable compositions comprising compounds
of the present invention and derivatives thereof, in combination with pharmaceutically
acceptable carriers diluents or adjuvants.

By "pharmaceutically acceptable derivatives" is meant any pharmaceutically acceptable salt, ester, or salt of such ester, of compounds of formula (I) or (II) or any other compound such as a prodrug which, upon administration to the recipient, is capable of providing (directly or indirectly) compounds of formula (I) or (II) or an active metabolite or residue
5 thereof.

The present invention also provides pharmaceutical compositions which comprise a pharmaceutically effective amount of a compound of the invention, or pharmaceutically acceptable salts thereof, and preferably, a pharmaceutically acceptable carrier, diluent or
10 adjuvant. The term "pharmaceutically effective amount" is the amount of compound required upon administration to a mammal in order to induce analgesia. Also, the term "opioid receptor agonizing amount" refers to the amount of compound administered to a mammal necessary to bind and/or activate opioid receptors in vivo.

15 Therapeutic methods of this invention comprise the step of treating patients in a pharmaceutically acceptable manner with those compounds or compositions. Such compositions may be in the form of tablets, capsules, caplets, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

20

In order to obtain consistency of administration, it is preferred that a composition of the invention is in the form of a unit dose. The unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients. For example, binding agents, such as acacia, gelatin, sorbitol, or polyvinylpyrrolidone; fillers,
25 such as lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants such as magnesium stearate; disintegrants, such as starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.

The compounds may be administered orally in the form of tablets, capsules, or granules containing suitable excipients such as starch, lactose, white sugar and the like. The compounds may be administered orally in the form of solutions which may contain coloring and/or flavoring agents. The compounds may also be administered sublingually in the form of tracheas or lozenges in which each active ingredient is mixed with sugar or corn syrups, flavoring agents and dyes, and then dehydrated sufficiently to make the mixture suitable for pressing into solid form.

The solid oral compositions may be prepared by conventional methods of blending, filling, tableting, or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

Liquid oral preparations may be in the form of emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may or may not contain conventional additives. For example suspending agents, such as sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, or hydrogenated edible fats; emulsifying agents, such as sorbitan monooleate or acaci; non-aqueous vehicles (which may include edible oils), such as almond oil, fractionated coconut oil, oily esters selected from the group consisting of glycerine, propylene glycol, ethylene glycol, and ethyl alcohol; preservatives, for instance methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate, n-propyl parahydroxybenzoate, or n-butyl parahydroxybenzoate of sorbic acid; and, if desired, conventional flavoring or coloring agents.

The compounds may be injected parenterally; this being intramuscularly, intravenously, or subcutaneously. For parenteral administration, the compound may be used in the form of sterile solutions containing other solutes, for example, sufficient saline or glucose to make the solution isotonic. For parenteral administration, fluid unit dosage forms may be prepared by utilizing the compound and a sterile vehicle, and, depending on the concentration employed, may be either suspended or dissolved in the vehicle. Once in solution, the compound may be injected and filter sterilized before filling a suitable vial or ampoule and subsequently sealing the carrier or storage package. Adjuvants, such as a local anesthetic, a preservative or a buffering agent, may be dissolved in the vehicle prior to use. Stability of the pharmaceutical composition may be enhanced by freezing the composition after filling the vial and removing the water under vacuum, (e.g., freeze drying the composition). Parenteral suspensions may be prepared in substantially the same manner, except that the compound should be suspended in the vehicle rather than being dissolved, and, further, sterilization is not achievable by filtration. The compound may be sterilized, however, by exposing it to ethylene oxide before suspending it in the sterile vehicle. A surfactant or wetting solution may be advantageously included in the composition to facilitate uniform distribution of the compound.

The pharmaceutical compositions of this invention comprise a pharmaceutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. Typically, they contain from about 0.01% to about 99% by weight, preferably from about 10% to about 60% by weight, of a compound of this invention, depending on which method of administration is employed.

The compounds of the present invention can be administered in combination with one or more further therapeutic agents. Preferably, the one or more further therapeutic agent is selected from the group consisting of nonsteroidal anti-inflammatory drugs (NSAIDs),
5 acetaminophen, narcotics, antidepressants, anticonvulsants, corticosteroid, tramadol, sumatriptan, and capsaicin.

Without limitations, NSAIDs include aspirin (Anacin, Bayer, Bufferin), ibuprofen (Motrin, Advil, Nuprin), naproxen sodium (Aleve) and ketoprofen (Orudis KT)

10

Without limitations, narcotics include drugs derived from opium (opiates), such as morphine and codeine, and synthetic narcotics (opioids), such as oxycodone, methadone and meperidine (Demerol).

15 Without limitations, antidepressants include amitriptyline (Elavil), trazodone (Desyrel) and imipramine (Tofranil) may be used with other analgesics. These drugs are especially useful for neuropathic, head and cancer pain.

Without limitations, anticonvulsants include drugs developed for epilepsy, these drugs,
20 such as phenytoin (Dilantin) and carbamazepine (Tegretol), can also help control chronic nerve pain.

Tramadol (Ultram) is a synthetic analgesic used primarily for chronic pain, but is also prescribed for acute pain.

25

Sumatriptan (Imitrex), may reduce pain from migraine headache by constricting blood vessels.


Capsaicin (Zostrix), a topical cream made from an extract of red peppers, can help relieve skin sensitivity resulting from shingles. Capsaicin can also be used to treat pain from arthritis, cluster headaches, diabetic neuropathy and pain after mastectomy.

- 5 In another aspect of the invention, compounds may be used to identify opioid receptors from non-opioid receptors. For such use, compounds of the invention are radiolabeled e.g. by incorporating ^3H or ^{14}C within its structure or by conjugation to ^{125}I . Such radiolabeled forms can be used directly to identify the presence of opioid receptors and in particular μ opioid receptors in a receptor population. This can be achieved by incubating
- 10 membrane preparations with a radiolabeled compound of the invention. The presence and or amount of opioid receptors in the preparation is determined from the difference in membrane-bound radioactivity against a control preparation devoid of opioid receptors. Furthermore, radiolabeled forms of the present compounds can be exploited to screen for more potent opioid ligands, by determining the ability of the test ligand to displace the
- 15 radiolabeled compound of the present invention.

To further assist in understanding the present invention, the following non-limiting examples are provided. Certain abbreviations used throughout the examples can be found in the Aldrich Chemical Company and Bachem catalogues.

EXAMPLE 1

Synthesis of trans-7-Amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol, hydrochloride



EXAMPLE 1**Synthesis of trans and cis-7-Amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol, hydrochloride**

5

Step 1 : 7-Methoxy-1,1-dimethyl-3,4-dihydro-1H-naphthalen-2-one (A)

To a solution of 7-methoxy-1-methyl-3,4-dihydro-1H-naphthalen-2-one (1.95g, 10.3
10 mmol) in THF (30 ml) was added NHMDS (11.3 mmol, 11.3 ml, 1M in THF) at 0°C under
nitrogen. The resulted solution was stirred at 0°C for 1 hr. Iodomethane (7.29 g, 3.19 ml,
51.3 mmol) was added and stirred for an additional 3 hrs. 10% KHSO₄ aqueous solution
was added to acidify the reaction mixture, diluted with brine, extracted with ethylacetate,
washed with brine, dried over MgSO₄, filtered. The filtrate was evaporated under *vacuo*.
15 The residue was purified by chromatography using ethylacetate : hexane (0.9 : 9.5) as
eluant to give the desired product as white solid. (1.77 g, 85%). ¹H NMR (CDCl₃) δ:
7.08(d, 1H, J=8.3Hz), 6.88(d, 1H, J=2.7Hz), 6.74(dd, 1H, J=2.7 and 8.3Hz), 3.80(s, 3H),
3.03(t, 2H, J=6.6Hz), 2.65(t, 2H, J=6.6Hz), 1.42(s, 6H). ¹³C NMR (CDCl₃) δ : 213.7,
157.8, 143.9, 128.1, 126.5, 111.3, 110.4, 54.4, 46.9, 36.5, 26.8, 25.8.

20

Step 2 : 7-Methoxy-1,1-dimethyl-3-methylsulfanyl-3,4-dihydro-1H-naphthalen-2-one(B)

To a solution of 7-methoxy-1,1-dimethyl-3,4-dihydro-1H-naphthalen-2-one (1.72 g, 8.40
25 mmol) in THF (20 ml) was added LHMDs (8.82 mmol, 8.82 ml, 1M in THF) at -78°C
under nitrogen, and then the temperature was raised to 0°C and stirred for 1 hr. The
solution was cooled to -78°C and methylmethanathiosulfonate (0.87 ml, 1.06g, 8.40mmol)
was added and stirring was continued for 4hr at 0°C, then room temperature for 1hr. The
reaction mixture was quenched with 1N HCl (2ml). Then, it was partitioned between
30 ethylacetate and brine, washed with sat. NaHCO₃ aqueous solution, brine, then dried over

MgSO₄, filtered, and evaporated under *vacuo*. The crude product was purified by flash column chromatography using ethylacetate : hexane (0.5 : 9.5 V/V) as eluant to give the desired product as white solid (2.07 g, 89%). ¹H NMR (CDCl₃) δ: 7.06(d, 1H, J=7.2Hz), 6.89(d, 1H, J=2.5Hz), 6.73(dd, 1H, J=7.2 and 2.5Hz), 3.79(s, 3H), 3.43(m, 1H), 3.40(m, 1H), 3.05(m, 1H), 2.05(s, 3H), 1.61(s, 3H), 1.37(s, 3H). ¹³C NMR (CDCl₃) δ: 208.3, 159.2, 144.6, 129.4, 124.0, 111.8, 110.9, 55.1, 50.2, 46.5, 32.7, 29.6, 27.2, 14.7.

Step 3 : 7-Methoxy-1,1-dimethyl-3-methylsulfanyl-3,4-dihydro-1H-naphthalen-2-one oxime (C)

10

To a solution of 7-methoxy-1,1-dimethyl-3-methylsulfanyl-3,4-dihydro-1H-naphthalen-2-one (0.265 g, 1.05 mmol) in pyridine (5 ml) was added hydroxylamine hydrochloride (1.09 g, 15.7mmol). The mixture was stirred under nitrogen at 85°C overnight. The solution was cooled to room temperature, poured into water, extracted with ethylacetate, washed with 10% KHSO₄ aqueous solution, brine, dried over MgSO₄, filtered. The filtrate was evaporated under *vacuo*. The crude product was purified by flash column chromatography using ethylacetate :Hexane (1 :9) as eluant to give the desired product as white solid (0.177g, 63%). ¹H NMR (CDCl₃) δ: 8.80(br, 1H), 7.05(d, 1H, J=8.2Hz), 6.93(d, 1H, J=2.5Hz), 6.73(dd, 1H, J=8.2 and 2.5Hz), 4.91(t, 1H, J=3.0Hz), 3.81(s, 3H), 3.26(dd, 1H, J=15.6 and 5.0Hz), 2.96(dd, 1H, J=15.6 and 3.0Hz), 2.15(s, 3H), 1.76(s, 3H), 1.48(s, 3H). ¹³C NMR (CDCl₃) δ: 164.5, 159.1, 145.0, 129.6, 129.4, 111.8, 111.0, 55.3, 39.8, 35.9, 32.9, 32.4, 30.8, 15.1.

20

Step 4 : 7-Methoxy-1,1-dimethyl-3-methylsulfanyl-3,4-dihydro-1H-naphthalen-2-ylamine (mixture of cis and trans) (D)

- 5 To a solution of 7-methoxy-1,1-dimethyl-3-methylsulfanyl-3,4-dihydro-1H-naphthalen-2-one oxime (1.13g, 4.21 mmol) and sodium borohydride (0.669g, 17.69mmol) in 1,2-dimethoxyethane (20 ml) was added titanium tetrachloride (8.84 ml, 8.84mmol, 1M in dichloromethane) dropwise under nitrogen at 0°C. The mixture was refluxed for 3 hrs. Then it was cooled to room temperature. Water (5ml) was added slowly, then Sat.NaHCO₃
- 10 aqueous solution (100ml) was added. It was extracted with ethylacetate (3x100ml). The combined extractions were dried over MgSO₄, filtered. The filtrate was evaporated under *vacuo*. The residue was purified by flash chromatography using ethylacetate as eluant to give the desired product as a mixture of cis :trans (1 :1) (0.655g, 61%). The mixture was further separated by reverse HPLC with gradient condition (10 to 50% acetonitrile / water
- 15 (0.1% TFA). The aqueous solution was basified with sat. NaHCO₃ aqueous solution, extracted with ethylacetate, dried over MgSO₄, filtered. The filtrate was evaporated under *vacuo* to give cis isomer (C-18 HPLC fast isomer, 0.230g, 21.5%) and trans isomer (C-18 HPLC slow isomer, 0.147g, 14%) as white solid. ¹H NMR (CDCl₃) δ: cis isomer, 6.97(d, 1H, J=8.2Hz), 6.84(d, 1H, J=2.8Hz), 6.69(dd, 1H, J=2.8 and 8.2Hz), 3.77(s, 3H), 3.67(oct, 1H, J=14.57, 6.31, and 2.20Hz), 2.75-2.97(m, 3H), 2.15(s, 3H), 1.49(s, br, 2H), 1.47(s, 3H), 1.25(s, 3H). ¹³C NMR (CDCl₃) δ: cis isomer, 158.40, 144.03, 129.57, 125.49, 112.37, 111.46, 57.22, 55.11, 44.41, 39.30, 32.53, 30.13, 26.48, 13.65. ¹H NMR (CDCl₃) δ: trans isomer, 6.95(d, 1H, J=8.5Hz), 6.87(d, 1H, J=2.4Hz), 6.70(dd, 1H, J=8.5 and 2.4Hz), 3.79(s, 3H), 3.18(m, 1H), 3.00-2.68(m, 3H), 2.15(s, 3H), 1.75(s, br, 2H), 1.46(s, 3H), 1.18(s, 3H). ¹³C NMR (CDCl₃) δ: trans isomer, 158.2, 146.4, 129.3, 126.1, 112.4, 111.6, 59.0, 55.2, 46.0, 40.2, 36.0, 27.9, 24.8, 12.1.
- 20
- 25

Step 5 : (±)-Trans-7-Amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol, hydrochloride (compound #1)

5 To a solution of trans-7-methoxy-1,1-dimethyl-3-methylsulfanyl-3,4-dihydro-1H-naphthalen-2-ylamine (0.147g, 0.585mmol) in dichloromethane (10 ml) was added borontribromide (1.76 ml, 1.76mmol, 1M in dichloromethane) dropwise at -78°C under nitrogen. The mixture was slowly warmed to room temperature and stirred overnight. Sat. NaHCO₃ aqueous solution (5ml) was added and stirred for 30 min. Then it was extracted
10 with ethylacetate, dried over MgSO₄, filtered. The filtrate was evaporated under vacuo. The residue was dissolved in dichloromethane and HCl (1.8ml, 1M in diethylether) was added. The solvent was evaporated. The residue was redissolved in dichloromethane, then it was added to hexane to precipitate the product. The precipitate was filtered off to give the desired product as white solid (0.135g, 89%). ¹H NMR (CD₃OD) δ: 6.92(d, 1H, J=8.2Hz), 6.80(d, 1H, J=2.4Hz), 6.63(dd, 1H, J=8.2 and 2.4Hz), 3.37(d, 1H, J=11.2Hz),
15 3.20-3.00(m, 3H), 2.20(s, 3H), 1.52(s, 3H), 1.29(s, 3H). ¹³C NMR (CD₃OD) δ: 157.0, 147.3, 130.4, 126.0, 114.7, 114.0, 60.3, 47.0, 40.9, 37.0, 28.5, 25.4, 11.8. LRMS, m/z, M+1, 238.0.


20

Step 6 : (±)-Cis-7-Amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol, hydrochloride (compound #2)

To a solution of cis-7-methoxy-1,1-dimethyl-3-methylsulfanyl-3,4-dihydro-1H-naphthalen-
25 2-ylamine (0.230g, 0.905 mmol) in dichloromethane (10 ml) was added borontribromide (2.71ml, 2.71mmol, 1M in dichloromethane) dropwise at -78°C under nitrogen. The mixture was slowly warmed to room temperature and stirred overnight. Sat. NaHCO₃ aqueous solution (5ml) was added and stirred for 30 min. Then it was extracted with ethylacetate, dried over MgSO₄, filtered. The filtrate was evaporated under *vacuo*. The
30 residue was dissolved in dichloromethane and HCl (1.8ml, 1M in diethylether) was

added. Solvent was evaporated. The residue was redissolved in dichloromethane. Then it was added to hexane to precipitate the product. The precipitate was filtered off to give the desired product as white solid (0.200g, 80%). ^1H NMR (CD_3OD) δ : 6.96(d, 1H, $J=8.3\text{Hz}$), 6.81(d, 1H, $J=2.4\text{Hz}$), 6.66(dd, 1H, $J=2.4$ and 8.3Hz), 3.65(oct, 1H, $J=2.2$, 8.0, and 14.6Hz), 3.47(d, 1H, $J=2.2\text{Hz}$), 3.11(dd, 1H, $J=2.2$ and 8.0Hz), 2.58(dd, 1H, $J=8.0$ and 14.6Hz), 2.24(s, 3H), 1.54(s, 3H), 1.39(s, 3H). ^{13}C NMR (CD_3OD) δ : 157.3, 144.9, 130.8, 125.5, 114.7, 114.1, 57.9, 45.4, 39.9, 33.1, 31.2, 27.2, 13.5. LRMS, m/z , $M+1$, 238.1.

EXAMPLE 2
Synthesis of
trans-7-Amino-8,8-diethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol, hydrochloride (COMPOUND #3)



EXAMPLE 2**Synthesis of**

(±)-Trans-7-Amino-8,8-diethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol,
5 **hydrochloride (compound #3)**

Step 1 : 1,1-Diethyl-7-methoxy-3,4-dihydro-1H-naphthalen-2-one (A)

To a solution of 7-methoxy-2-tetralone (4.26 g, 24.18 mmol) in DMF (100 mL) at 0° C was
10 1 eq of sodium hydride (60% in oil) (1g, 41.6 mmol). After 30 minutes, 1.25 eq of
iodoethane was added (2.5 mL, 30.2 mmol), then after 30 min, the other equivalent of
sodium hydride (1g), after 30 min the iodoethane was added (2.5 mL, 30.2 mmol). The
resulting purpule solution was stirred for 1h at 0°C then stirred for over night at r.t. The
mixtutre was quenched with water, then diluted with Et₂O. The organic layer was then
15 washed with H₂O, brine, dried over MgSO₄, filtered then evaporated. The residu was
purified by a flash chromatography (5%AcOEt/ Hex) (4.40g, 78%).

¹H NMR (CDCl₃) : 7.12 (1H, d, J=8.0Hz, H₅), 6.78 (2H, m, H₆ and H₈), 3.84 (3H, s,
OCH₃), 2.97 (2H, t, J=6.0 Hz, PhCH₂), 2.6 (2H, t, J=6.0 Hz, CH₂CO), 2.10 (2H, m, CH₂),
1.71 (2H, m, CH₂), 0.63 (6H, t, J=7.5 Hz, CH₃).

20

Step 2 : 1,1-Diethyl-7-methoxy-3,4-dihydro-1H-naphthalen-2-one oxime (B)

1,1-diethyl-7-methoxy-3,4-dihydro-1H-naphthalen-2-one (4.40g, 18.96 mmol) in dry
pyridine (20 mL) with the hydroxylamine hydrochloride salt (10.54 g, 151.7 mmol) was
25 heated to 80 °C for one day. The mixture was cooled down to r.t., then the pyridine was
removed under vaccum. The green gum was dissolved with AcOEt, washed with H₂O, HCl
10%, H₂O, brine , dried over MgSO₄ and filtered through a small silica pad. The crude
compound was used without any other purification (4.69g, 100%).

¹H NMR (CDCl₃) : 7.94 (1H, s, OH), 7.06 (1H, d, J=8 Hz, H₅), 6.84 (1H, d, J=2.5 Hz, H₈), 6.73 (1H, dd, J=2.5 and 8 Hz, H₆), 3.83 (3H, s, OCH₃), 2.80-2.75 (4H, m, PhCH₂CH₂), 2.08 (2H, m, CH₂), 1.85 (2H, m, CH₂), 0.68 (6H, t, J=7.5 Hz, CH₃).

5

Step 3 : 7,7-Diethyl-5-methoxy-1a,2,7,7a-tetrahydro-1H-1-aza-cyclopropa[b]naphthalene (C)

To a solution of the 1,1-diethyl-7-methoxy-3,4-dihydro-1H-naphthalen-2-one oxime
10 (4.68g, 18.96 mmol) in dry THF (100 mL) at 0°C was added the diethylamine (4.9 mL, 47.4 mmol) and the LAH (95% powder) (2.16g, 56.9 mmol). The mixture was stirred at 0°C for 15 min then heated to reflux for 3h. The gray solution was cooled down to 0°C, quenched with brine and diluted with AcOEt. The organic layer was decanted, washed with H₂O (2x), brine, dried over MgSO₄, filtered then evaporated. The residu was purified by a
15 flash chromatography (3% MeOH/ CH₂Cl₂) (3.889 g, 89%).

¹H NMR (CDCl₃) : 6.99 (1H, d, J=8 Hz, H₅), 6.76 (2H, m, H₆ and H₈), 3.13 (2H, m, CHCH), 2.40 (1H, broad, NH), 2.10-2.05 (2H, m), 1.84 (1H, m), 1.62 (4H, m, CH₂), 1.02 (3H, t, J=7.5 Hz, CH₃), 0.75 (3H, t, J=7.5hz, CH₃).

20

Step 4 : 7,7-Diethyl-1a,2,7,7a-tetrahydro-1H-1-aza-cyclopropa[b]naphthalen-5-ol (D)

To a solution of 7,7-diethyl-5-methoxy-1a,2,7,7a-tetrahydro-1H-1-aza-cyclopropa[b]naphthalene
25 (3.889g, 16.81 mmol) in CH₂Cl₂ (170 mL) at -78°C was added the BBr₃ (1M in CH₂Cl₂) (33.6 mL, 33.62 mmol). The mixture was kept at -78°C for 30 min then to 0°C for 1.5h. The mixture was quenched by NaHCO₃, diluted with AcOEt. The organic layer was washed with H₂O, brine, dried over MgSO₄, filtered then evaporated. The residu was purified by a flash chromatography (3% MeOH /CH₂Cl₂) (2.917g, 80%).

¹H NMR (CDCl₃) : 6.93 (1H, d, J=8 Hz, H₅), 6.68 (1H, d, J=2.5 Hz, H₈), 6.64 (1H, dd, J=8 and 2.5 Hz, H₆), 3.12 (2H, m, CHCH), 2.42 (1H, broad, OH), 2.14 (1H, broad, NH), 2.04 (1H, m), 1.82 (1H, m), 1.65 (4H, m, CH₂), 1.02 (3H, t, J=7.5 Hz, CH₃), 0.75 (3H, t, J=7.5 Hz, CH₃).

5

Step 5 : 5-*tert*-Butoxycarbonyloxy-7,7-diethyl-1a,2,7,7a-tetrahydro-1-aza-cyclopropa[*b*]naphthalene-1-carboxylic acid *tert*-butyl ester (D)

To a solution of diethyl-1a,2,7,7a-tetrahydro-1*H*-1-aza-cyclopropa[*b*]naphthalen-5-ol (1.5g, 6.90 mmol) in CH₂Cl₂ (30 mL) at r.t was added the (Boc)O (3.77g, 17.26 mmol), the triethylamine (3.85 mL, 27.6 mmol) and DMAP (cat). The mixture was stirred at r.t for over night. The mixture was quenched by NH₄Cl, diluted with AcOEt. The organic layer was washed with H₂O, brine, dried over MgSO₄, filtered then evaporated. The residu was purified by a flash chromatography (5% to 25% AcOEt/Hex) (2.44g, 84%).

¹H NMR (CDCl₃) : 7.05-6.95 (3H, m, Har), 3.29 (1H, d, J=17 Hz, PhCH_{HH}), 3.04 (1H, dd, J=2Hz and 17Hz, PhCH_{HH}), 2.94 (1H, m), 2.67 (1H, d, J=6.5 Hz), 2.05-1.95 (2H, m), 1.65-1.50 (11H, m), 1.43 (9H, s, *t*-butyl), 1.11 (3H, t, J=7.5 Hz, CH₃), 0.72 (3H, t, J=7.5 Hz, CH₃).

20

Step 6 : Thioacetic acid *S*-(trans-3-*tert*-butoxycarbonylamino-6-*tert*-butoxycarbonyloxy-4,4-diethyl-1,2,3,4-tetrahydro-naphthalen-2-yl) ester (E)

5-*tert*-Butoxycarbonyloxy-7,7-diethyl-1a,2,7,7a-tetrahydro-1-aza-cyclopropa[*b*]naphthalene-1-carboxylic acid *tert*-butyl ester (218 mg, 0.52 mmol) and the thiolacetic acid (2 mL) was stirred at r.t for over night. The mixture was diluted with Et₂O (50 mL), washed with H₂O, NaHCO₃ (3x), H₂O, brine, dried over MgSO₄. The residu was purified by a flash chromatrgraphy (10% AcOEt/Hex) (234 mg, 91%).

¹H NMR (CDCl₃) : 7.05-6.95 (3H, m, Har), 4.80 (1H, d, J=10.5 Hz, NH), 4.15-4.00 (2H, m, CHCH), 3.17 (1H, dd J=5 Hz and 17 Hz, PhCH_{HH}), 2.97 (1H, dd, J=12Hz and 17Hz,

30

PhCHH), 2.40 (3H, s, SCOCH₃), 1.86 (1H, m), 1.70 (2H, m), 1.60-1.55 (11H, m), 1.47 (9H, s, *t*-butyl), 0.89 (3H, t, J=7.5 Hz, CH₃), 0.71 (3H, t, J=7.5 Hz, CH₃).

5 **Step 7 : Carbonic acid 7-*tert*-butoxycarbonylamino-8,8-diethyl-trans-6-mercapto-5,6,7,8-tetrahydro-naphthalen-2-yl ester *tert*-butyl ester (F)**

Thioacetic acid *S*-(trans-3-*tert*-butoxycarbonylamino-6-*tert*-butoxycarbonyloxy-4,4-diethyl-1,2,3,4-tetrahydro-naphthalen-2-yl) ester (234 mg, 0.47 mmol) in MeOH (5 mL)
10 was added the sodium methoxide (54 μ L, 0.95mmol) and stirred at 0°C for 30 min. The mixture was quenched with H₂O, diluted with Et₂O (50 mL), washed with H₂O, HCl (10%), H₂O, brine, dried over MgSO₄. The residu was used without any other purification (151 mg, 71%).

¹H NMR (CDCl₃) : 7.10-6.95 (3H, m, Har), 4.58 (1H, d, J=11.0 Hz, NH), 4.00 (1H, t, J=11Hz, CHNH), 3.40-3.25 (2H, m), 2.98 (1H, m), 1.80-1.45 (22H, m), 0.80-0.70 (6H, m, CH₃).
15


Step 8 : Carbonic acid 7-*tert*-butoxycarbonylamino-8,8-diethyl-trans-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-yl ester *tert*-butyl ester (G)
20

To a solution of carbonic acid 7-*tert*-butoxycarbonylamino-8,8-diethyl-trans-6-mercapto-5,6,7,8-tetrahydro-naphthalen-2-yl ester *tert*-butyl ester (28.2 mg, 0.062 mmol) in acetone (2 mL) was added the iodomethane (20 μ L, 0.31mmol) and the potassium carbonate (26 mg, 0.18 mmol), and stirred at reflux for 4 h. The mixture was quenched with H₂O, diluted
25 with Et₂O (50 mL), washed with H₂O, brine, dried over MgSO₄. The residu was purified by a flash chromatography (10% AcOEt/Hex) (21.2 mg, 73%) .

¹H NMR (CDCl₃) : 7.08 (1H, d, J=8.5 Hz, H₅), 7.00-6.95 (2H, m, H₆ and H₈), 4.56 (1H, d, J=11 Hz, NH), 4.09 (1H, t, J=11.0 Hz, CHNH), 3.25-3.00 (3H, m), 2.15 (3H , broad, SCH₃), 1.76 (4H, m, CH₂), 1.57 (9H, s, *t*-butyl), 1.50 (9H, s, *t*-butyl), 0.73 (6H, m, CH₃).
30

Step 9 : (±)-Trans-1,1-diethyl-7-hydroxy-3-methylsulfanyl-1,2,3,4-tetrahydro-naphthalen-trans-2-yl-ammonium; chloride (compound #3)

- 5 To a solution of Carbonic acid 7-*tert*-butoxycarbonylamino-8,8-diethyl-trans-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-yl ester *tert*-butyl ester (21.2 mg, 0.045 mmol), in CH₂Cl₂(2 mL) was added the TFA (0.2 mL). The solution was stirred at r.t for 3h. The volatil was removed and co-evaporated with CH₂Cl₂. The final purity was verified by HPLC reversed phased (0% to 50 % of CH₃CN +0.01% TFA in 25 min, λ= 215 nM
- 10 Rt=11.28 min, 97%) (14.8 mg, 86%).
- ¹H NMR (CD₃OD) : 6.99 (1H, d, J=8.5 Hz, H₅), 6.70-6.65 (2H, m, H₆ and H₈), 4.46 (1H, d, J=11 Hz,), 3.30-3.25 (2H, m), 2.98 (1H, dd, J=5.5 Hz and 11 Hz, PhCH_{HH}), 2.22 (3H, s, SCH₃), 2.15 (1H, m, CH_{HH}CH₃), 1.77 (2H, m, CH₂CH₃), 1.64 (1H, m, CH_{HH}CH₃), 0.85 (3H, t, J=7.5 Hz, CH₃), 0.75 (3H, t, J=7.5 Hz, CH₃).

EXAMPLE 3 -**1,1-Dimethyl-7-hydroxy-3-phenylsulfanyl-1,2,3,4-tetrahydro-naphthalen-trans-2-yl-ammonium; chloride**

EXAMPLE 3 - (\pm)-Trans-1,1-dimethyl-7-hydroxy-3-phenylsulfanyl-1,2,3,4-tetrahydro-naphthalen-trans-2-yl-ammonium; chloride (compound #4)

5 **Step 1 : 7-Methoxy-1,1-dimethyl-3,4-dihydro-1H-naphthalen-2-one oxime (A)**

7-Methoxy-1,1-dimethyl-3,4-dihydro-1H-naphthalen-2-one (used as a crude from example 1, step1, 128.8 g, 0.63 mol) and hydroxylamine hydrochloride (350g, 5.04mol) in pyridine (360 ml) were heated up to 80°C. The reaction mixture was stirred for 15h at 80-90°C.

10 Pyridine was removed under reduced pressure. The residue was partitioned between ethylacetate (2.5l) and water (1l). Water layer was separated and washed with ethyl acetate (1l). Ethyl acetate solution was washed with 10% aq. KHSO₄ (1l), dried over Na₂SO₄. Ethyl acetate was removed under reduced pressure and the residue was crystallized from acetone to give 101.2 g of target compound. Mother liquid was concentrated to dryness and
15 crystallized from acetone to give second crop (11.4 g).
112.6g (82%) of the desired product was obtained. ¹H NMR (CDCl₃), d 9.15 (s, 1H), 7.06 (d, 1H, J=7.4 Hz) 6.92 (1H, d, J=2.4Hz), 6.75 (dd, 1H, J= 7.4 and 2.4Hz), 3.82 (s, 3H), 2.78-2.95 (m, 4H), 1.5 (s, 6H).

20 **Step 2: 5-Methoxy-7,7-dimethylmethyl-1a,2,7,7a-tetrahydro-1H-1-aza-cyclopropa[b]naphthalene(B)**

LiAlH₄ (1M in THF ,1.43l, 1.43 mol) was added dropwise to a solution of diethylamine (108 ml, 1.05 mol) and 7-Methoxy-1,1-dimethyl-3,4-dihydro-1H-naphthalen-2-one oxime
25 (112.6g, 0.51 mol) in THF (700ml) at 0-8°C. The reaction mixture was brought to reflux and refluxed for 1h. An excess of LiAlH₄ was quenched with water solids were filtered off and washed with 25% MeOH in acetone followed by 5% aq ammonia in MeOH. The solution was concentrated to dryness and the crude was purified by flash chromatography using ethylacetate/methanol (1 to 4%) with 0.2% of ammonia hydroxide. Fraction

containing desired product were concentrated to dryness and the residue was crystallized from hexane to give 58g (56%) of the target compound.

The mother liquid was purified by flash chromatography using hexane/ethyl acetate (1/1) followed by ethyl acetate to give 10g (10%) of the target compound.

5 ¹H NMR (CDCl₃), d 6.98(d, 1H, J=7.8Hz) 6.851H, d, J=2.4Hz), 6.70(dd, 1H, J= 7.8 and 2.4Hz), 3.15 (br s, 2H), 2.51(br s, 1H), 2.15 (br s, 1H), 1.75 (s, 3H), 1.22 (s, 3H).

10 **Step 3: 7-Methoxy-1,1-dimethyl-3-phenylsulfanyl-1,2,3,4-tetrahydro-naphthalen-trans-2-yl-amine(C)**

4-Methoxy-2,2-dimethyl-1a,2,7,7a-tetrahydro-1H-1-aza-cyclopropa(b)naphthalene (0.352g, 1.73 mmoles) was dissolved in 2 ml of ethyl alcohol. To the stirred solution, triethylamine (0.88ml, 6.3 mmoles) and thiophenol (0.53 ml, 5.16 mmoles) were added subsequently.

15 The reaction mixture was stirred for 24 hours at room temperature until TLC shows complete reaction. The solvent was removed by vacuum distillation. Resulting dark yellow oil, was dissolved in minimum quantity of dichloromethane and applied on Mega-Bond Elut cartridge. The desired product was isolated by elution with ethyl acetate and hexane mixture (1 :3), (0.373g, 65%).

20 ¹H NMR (CDCl₃) d : 7.51(d, 2H), 7.30(m, 3H), 6.89(m, 2H), 6.68(m, 1H), 3.79(s, 3H), 3.44(m, 1H), 3.11(dd, 1H), 2.88(dd, 2H), 1.66(br, 2H), 1.48(s, 3H), 1.20(s, 3H) ; ppm.

Step 4

25 **1,1-Dimethyl-7-hydroxy-3-phenylsulfanyl-1,2,3,4-tetrahydro-naphthalen-trans-2-yl-ammonium; chloride (D)**


Trans-7-Methoxy-1,1-dimethyl-3-phenylsulfanyl-1,2,3,4-tetrahydro-naphthalen-yl-amine (0.373g, 1.19 mmoles) was dissolved at 0°C in dichloromethane (30ml). Solution of boron tribromide in dichloromethane (3.57 ml of 1M soln.) was slowly added. It was stirred for

30

and allowed to reach room temperature within 2 hours. Stirring was continued for overnight. Saturated sodium bicarbonate was added to quench reaction. The product was extracted using dichloromethane (4x 30ml). Crude mixture was purified on Mega Bond Elut cartridge eluting with ethyl acetate. Fractions containing pure product were combined,
5 evaporated and evacuated under high vacuum. The resulting solid was dissolved in warm methanol (10 ml) place in an ice bath and treated with 1.2 ml of 1M HCl in Et₂O. It was stirred for 25 min, evaporated to dryness, redissolved in 30 ml of water and freeze dried to give 0.1927 g (48%) of white solid.

¹H NMR (CD₃OD) δ : 7.62(d, 2H, J=6.46Hz), 7.41(d, 3H, J=7.3Hz), 7.79(dd, 2H, J=2Hz,
10 J=7Hz), 6.59(dd, 1H, J=2Hz, J=7Hz), 3.54(m, 1H), 3.35(d, 1H), 3.11(dd, 1H, J=4.8Hz, J=16Hz), 2.84(dd, 1H, J=16Hz, J=12Hz), 1.52(s, 3H), 1.32(s, 3H) ; ppm.

EXAMPLE 4



Step 1. (-)-Trans-[Carbonic acid 2-(S)-isopropyl-5-(R)-methyl-cyclohex-(R)-yl ester 7-(R)-(2-(S)-isopropyl-5-(R)-methyl-cyclohex-(R)-yloxycarbonyl-(R)-amino)-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydronaphthalen-2-yl ester].

5

Trans-7-Amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol (0.150g, 0.6 mmoles), was dissolved in 30 ml of dichloromethane at 0°C. To a stirred solution, pyridine (0.240ml, 3mmoles), and (L)-(-)-menthyl chloroformate (0.320ml, 1.5 mmoles) were added. The mixture was allowed to reach room temperature and it was further stirred
10 for 2 hours. Aqueous sodium bicarbonate was added and stirred for 20 minutes. Organic phase was separated and aqueous layer was extracted with three portions of dichloromethane. Organic extracts were dried over anhydrous sodium sulfate, filtered and evaporated. Remaining oil was applied on preparative TLC plate and eluted three times with mixture of ethylacetate and hexane, 1 :20. Less polar fraction contains (+)
15 diastereomer (0.12 g), more polar fraction contains (-) diastereomer (0.09g).
¹H NMR (400 MHz) (CDCl₃; d; ppm) : 7.12(m, 1H), 7.05(m, 1H), 6.98(m, 1H), 4.6(m, 3H), 3.9(t, 1H, J=6Hz), 3.25(m, 1H), 3.15(m, 1H), 3.0(m, 1H), 2.2-2.0(m, 5H), 1.7(m, 4H), 1.5(m, 3H), 1.4(, m, 3H), 1.2(m, 3H), 1.1(m, 4H), 0.8-0.95(m, 21H).

20 **Step 2. (-)-Trans-7-Hydroxy-1,1-dimethyl-3-methylsulfanyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-carbamic acid 2-isopropyl-5-methylcyclohexyl ester.**

(-)-Trans-[Carbonic acid 2-(S)-isopropyl-5-(R)-methyl-cyclohex-(R)-yl ester 7-(R)-(2-(S)-isopropyl-5-(R)-methyl-cyclohex-(R)-yloxycarbonyl-(R)-amino)-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydronaphthalen-2-yl ester], (0.09g, 0.2mmoles), was dissolved
25 in 2 ml of methyl alcohol containing potassium carbonate (0.01g). It was stirred for 5 hours at room temperature. Methyl alcohol was evaporated and the residue was applied on silicagel column. The product was eluted using ethylacetate : hexane mixture 1 : 5, (0.021g).

¹H NMR (400 MHz) (CD₃OD; d; ppm) : 6.7(d, 0.8H, J=10Hz), 6.65(d, 1H, J=8Hz), 6.5(d, 1H, J=2Hz), 6.3(dd, 1H, J=2Hz, J=8Hz), 4.6(s, 3H), 4.3(m, 1H), 3.45(m, 1H), 3.1(m, 3H), 2.9(dd, 1H, J=6Hz, J=12Hz), 2.8(m, 1H), 2.7(m, 1H), 1.9(s, 2H), 1.85(m, 1H), 1.5(d, 1H, J=10Hz), 1.3-1.2(m, 2H), 1.1(s, 2H), 0.95(s, 2H), 0.7(d, 3H, J=5Hz), 0.6(d, 3H, J=5Hz).


5

Step 3. (-)-Trans-7-amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol hydrochloride.

(-)-Trans-7-Hydroxy-1,1-dimethyl-3-methylsulfanyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-
 10 carbamic acid 2-isopropyl-5-methylcyclohexyl ester (0.021g), was dissolved in a mixture of acetic acid solution of HBr (36%) 0.5ml, and formic acid (1ml). The flask was sealed and heated at 58-60°C for 4 hours. The liquids were evaporated to dryness under vacuum and the residue was alkalized with aqueous ammonia. Alkaline solution was extracted with dichloromethane. Organic extracts were dried over sodium sulfate, filtered and evaporated.
 15 The residue was dissolved in MeOH (0.5ml) and 1M solution of HCl in ethyl ether (0.2ml) was added. It was stirred for 10 min., evaporated, dissolved in water (5ml) and freeze dried. Yield : 0.0125g of white solid ; $\alpha_D = -65^\circ$ (c=0.04, MeOH).

Compound #32


20 **Trans-(-)-7-amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol hydrochloride**



¹H NMR (CD₃OD; d; ppm) : 6.92(d, 1H, J=10 Hz), 6.78(d, 1H, J=3Hz), 6.63(dd, 1H, J=10Hz, J=3Hz), 3.31(1H), 3.10(m, 3H), 2.2(s, 3H), 1.5(s, 3H), 1.3(s, 3H).

25

Compound #33 Trans-(+)-7-amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydronaphthalen-2-ol hydrochloride




¹H NMR (CD₃OD; d; ppm) : 6.92(d, 1H, J=10 Hz), 6.78(d, 1H, J=3Hz), 6.63(dd, 1H, J=10Hz, J=3Hz), 3.31(1H), 3.10(m, 3H), 2.2(s, 3H), 1.5(s, 3H). 1.3(s, 3H).

In a similar manner as described in examples 1 to 4, the following compounds were also obtained:

Compound #5

(±)-Trans-7-hydroxy-1,1-dimethyl-3-(2-pyridylsulfanyl)-1,2,3,4-tetrahydronaphthalen-2-yl ammonium trifluoroacetate




¹H NMR (CD₃OD), d 8.49 (d, 1H, J=5Hz), 7.77-7.73(m, 1H), 7.49 (1H, d, J=8.1Hz), 7.27-7.24(m, 1H), 6.92 (d, 1H, J=8.4 Hz), 6.84 (1H, d, J=2.5Hz), 6.64 (dd, 1H, J= 8.4 and 2.5Hz), 4.23-4.15 (m, 1H), 3.60 (d, 1H, J=11.2 Hz), 3.28 (dd, 1H, J=18Hz and J=5.3 Hz), 3.05 (dd, 1H, J=18Hz, J=5.2 Hz), 1.55 (s, 3H), 1.43 (s, 3H)

Compound #6

(±)-Trans-7-hydroxy-1,1-dimethyl-3-(pyrimidin-2-ylsulfanyl)-1,2,3,4-tetrahydronaphthalen-2-yl ammonium chloride

5




¹H NMR (CD₃OD), d 8.28 (s, 1H), 8.27 (s, 1H), 6.87 (d, 1H, J=8.3 Hz), 6.77 (d, 1H, J=2.4Hz), 6.62-6.56. (m, 2H), 4.31 (d, 1H, J=11.6 Hz), 3.40-3.47 (m, 1H), 3.60 (d, 1H, J=11.2 Hz), 3.28 (dd, 1H, J=16.2Hz and J=5.3 Hz), 2.93 (dd, 1H, J=16.2Hz, J=5.2 Hz), 1.30 (s, 3H), 1.23 (s, 3H)

10

Compound #7

(±)-Trans-7-amino-6-(3-amino-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride

15




20

¹HNMR 7.06 (dd, 1H, J=7.9Hz, J=7.8Hz), 6.9 (dd, 1H, J=1.9Hz, J=1.8Hz), 6.82 (d, 1H, J=7.8 Hz), 6.77 (d, J=6.8Hz), 6.76 (s, 2H), 6.62-6.65 (m, 1H), 6.53 (dd, 1H, J=2.5, J=8.3 Hz), 3.86-3.3.94(m, 1H), 3.06 (dd, 1H J=5.3Hz, J=16.3Hz), 2.82 (s, 1H), 2.72(s, 1H), 1.41 (s, 3H), 1.18 (s, 3H)

Compound #8

(±)-Trans-7-amino-6-(4-methylthio-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydronaphthalen-2-ol hydrochloride

5




10

¹HNMR (CD₃OD), d 7.46 (dd, 2H, J=1.8Hz, J=8.4Hz), 7.24 (dd, 2H, J=1.8Hz, J=8.4Hz), 6.74-6.76 (m, 2H), 6.52 (dd, 1H, J=2.4Hz, J=8.3Hz). 3.29-3.36 (m, 1H), 3.00 (dd, 1H, J=5.3Hz, J=16.2Hz), 2.18-2.28 (m, 2H), 2.47 (s, 3H), 1.40 (s, 3H), 1.17 (s, 3H).

Compound #9

(±)-Trans-3-benzenesulfonylmethylsulfanyl-1,1-diethyl-7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl-ammonium; chloride

15




20

¹H NMR (MeOD) : 8.02 (2H, d, J=8.0 Hz), 7.80 (1H, m), 7.70 (2H, t, J=8.0 Hz), 6.96 (1H, d, J=8.0 Hz), 6.70 (2H, m), 4.58 (2H, s), 3.72 (1H, m), 3.62 (1H, d, J=11.5 Hz), 2.93 (1H, dd, J=11.5 Hz and 16 Hz), 2.13 (1H, m), 1.85-1.65 (3H, m), 0.86 (3H, t, J=7.5 Hz), 0.73 (3H, t, J=7.5 Hz).

Compound #10

(±)-Trans-3-carbamoylmethylsulfanyl-1,1-diethyl-7-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium; trifluoro-acetate

5




^1H NMR (DMSO) : 9.23 (1H, s), 8.47 (3H, broad), 7.70-7.60 (2H, broad), 6.91 (1H, d, $J=8.5$ Hz), 6.61 (1H, s), 3.58 (2H, s), 3.11 (1H, m), 2.94 (1H, m), 1.93 (1H, m), 1.82 (1H, m), 1.65 (1H, m), 1.54 (1H, m), 0.71 (3H, t, $J=7.5$ Hz), 0.57 (3H, t, $J=7.5$ Hz).

10

Compound #11

(±)-Trans-3-(diethoxy-phosphorylmethylsulfanyl)-1,1-diethyl-7-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium; chloride




15

^1H NMR (DMSO) : 9.23 (1H, s), 8.22 (3H, broad), 6.92 (1H, d, $J=8.5$ Hz), 6.61 (2H, m), 4.12 (4H, m), 3.20-3.15 (2H, m), 2.97 (1H, m), 1.95 (1H, m), 1.83 (1H, m), 1.65 (1H, m), 1.51 (1H, m), 1.27 (6H, m), 0.71 (3H, t, $J=7.5$ Hz), 0.60 (3H, t, $J=7.5$ Hz).

Compound #12

(±)-Trans-1,1-diethyl-7-hydroxy-3-(2-hydroxy-ethylsulfanyl)-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium; chloride

5




¹H NMR (MeOD) : 6.97 (1H, d, J=8.0 Hz), 6.70-6.65 (2H, m), 3.82 (2H, m), 3.50-3.40 (2H, mm),
10 3.00-2.85 (2H, m), 2.12 (1H, m), 1.80-1.60 (3h, m), 0.83 (3H, t, J=7.5 Hz), 0.73 (3H, t, J=7.5 Hz).

Compound #13

(±)-Trans-3-(5-amino-2H-[1,2,4]triazol-3-ylsulfanyl)-1,1-diethyl-7-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium; trifluoro-acetate


15



^1H NMR (MeOD) : 6.97 (1H, d, $J=8.5$ Hz), 6.70-6.65 (2H, m), 3.90 (1H, qd, $J=5.5$ Hz and 12 Hz), 3.76 (1H, d, $J=12$ Hz), 3.29 (1H, dd, $J=5.5$ Hz and 16.5 Hz), 2.11 (1H, m), 1.85-1.65 (3H, m), 0.88 (3H, t, $J=7.5$ Hz), 0.70 (3H, t, $J=7.5$ Hz).

5 **Compound #14**

(±)-Trans-3-(2-Ammonium-ethylsulfanyl)-7-hydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium dichloride




(400MHz, CD_3OD) δ : 6.8(3H, m), 3.8-2.5(8H, m), 1.5(3H, s), 1.32(3H, s).

10

Compound #15

(±)-Trans-3-(5-Amino-2*H*-[1,2,4]triazol-3-ylsulfanyl)-1,1-dimethyl-7-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium; chloride

15




ClH

(400MHz, $\text{DMSO}-\text{D}_6$) δ : 9.3(3H, bs), 8.3(3H, bs), 6.75(3H, m), 3.9-3.0(4H, m), 1.45(3H, s), 1.15(3H, s).

Compound #16

(±)-Trans-1,1-dimethyl-7-hydroxy-3-propylsulfanyl-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium; trifluoro-acetate




¹H NMR (DMSO) : 9.22 (1H, s), 8.04 (3H, bs), 6.87 (1H, d, J=8.5 Hz), 6.74 (1H, d, J=2.0 Hz), 6.74 (1H, dd, J=2.0 Hz and 8.5 Hz), 3.28 (1H, m), 3.15-3.05 (2H, m), 2.91 (1H, m), 2.75-2.60 (2H, m), 1.60 (2H, m), 1.44 (3H, s), 1.19 (3H, s), 0.98 (3H, t, J=7.5 Hz).

10 MS : 266 (MH⁺)

Compound #17

(±)-Trans-1,1-dimethyl-7-hydroxy-3-isopropylsulfanyl-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium; chloride




¹H NMR (DMSO) : 9.23 (1H, s), 8.14 (3H, bs), 6.87 (1H, d, J=8.5 Hz), 6.75 (1H, d, J=2.0 Hz), 6.59 (1H, dd, J=2.0 Hz and 8.5 Hz), 3.29 (1H, m), 3.25-3.10 (3H, m), 2.84 (1H, td, J=10.5 Hz and 6.5 Hz), 1.43 (3H, s), 1.30 (3H, d, J=6.5 Hz), 1.27 (3H, d, J=6.5 Hz), 1.22 (3H, s).

20 MS : 266 (MH⁺)

Compound #18

(±)-Trans-1,1-dimethyl-7-hydroxy-3-(2-hydroxy-ethylsulfanyl)-1,2,3,4-tetrahydronaphthalen-2-yl-ammonium; chloride



5


^1H NMR (DMSO) : 9.23 (1H, s), 8.14 (3H, bs), 6.87 (1H, d, $J=8.5$ Hz), 6.74 (1H, d, $J=2.0$ Hz), 6.58 (1H, dd, $J=2.0$ Hz and 8.5 Hz), 5.32 (1H, broad), 3.70-3.60 (2H, m), 3.20-3.05 (2H, m), 2.95-2.75 (3H, m), 1.44 (3H, s), 1.19 (3H, s).

MS : 268 (MH⁺)

10

Compound #19

(±)-Trans-3-ambamoylmethylsulfanyl-1,1-dimethyl-7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl-ammonium; trifluoro-acetate




15

^1H NMR (DMSO) : 9.23 (1H, s), 8.48 (3H, bs), 7.98 (1H, s), 7.59 (1H, s), 6.86 (1H, d, $J=8.0$ Hz), 6.74 (1H, s), 6.58 (1H, dd, $J=2.0$ Hz and 8.0 Hz), 3.55 (1H, d, $J=16.0$ Hz), 3.50-3.15 (3H, m), 2.99 (2H, d, $J=8.0$ Hz), 1.42 (3H, s), 1.17 (3H, s).

20

Compound #20


(±)-Trans-7-dimethylamino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol



¹H NMR (400MHz) (CDCl₃; d; ppm): 6.90 (1H, d), 6.78 (1H, d), 6.59 (1H, dd), 3.21 (1H, dd), 3.08 (1H, m), 2.93 (1H, dd), 2.64 (1H, d), 2.28 (6H, s) 2.21 (3H, s), 1.31 (3H, s), 1.30 (3H, s).

Compound #21


(±)-Trans-8,8-dimethyl-7-methylamino-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol



¹H NMR (400MHz) (CDCl₃; d; ppm): 6.90 (1H, d), 6.80 (1H, d), 6.61 (1H, dd), 3.05 (1H, m), 2.95 (1H, m), 2.67 (3H, s), 2.36 (1H, d), 2.19 (3H, s), 1.43 (3H, s, CH₃), 1.20 (3H, s, CH₃).

Compound #22

(±)-Trans-7-Amino-8,8-diethyl-6-phenylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol




¹H NMR (400MHz) (CDCl₃; d; ppm): 7.51 (1H, d), 7.27-7.34 (4H, m), 6.85 (1H, d), 6.66 (1H, d), 6.60 (1H, dd), 3.62 (1H, m), 3.12 (1H, dd), 2.83(1H,dd), 2.75-3.12 (2H, bs, NH₂),

1.84 (2H, m), 1.79 (1H, m), 1.67 (1H, m), 0.75 (3H, t, $J=7.5\text{Hz}$, CH_3), 0.64 (3H, t, $J=7.2\text{Hz}$, CH_3).

Compound #23


5 **(±)-Trans-8,8-dimethyl-trans-6-phenylsulfanyl-7-propylamino-5,6,7,8-tetrahydro-naphthalen-2-ol**



10 ^1H NMR (400MHz) (CDCl_3 ; d; ppm): 7.50 (2H, m), 7.32 (2H, m), 7.27 (1H, m), 6.81 (2H, m), 6.59 (1H, m), 3.77 (1H, m), 3.11 (1H, m), 2.89-3.02 (2H, m), 2.47-2.76 (2H, m), 1.56 (2H, bs), 1.44 (3H, s), 1.27 (3H, s), 0.94 (3H, t, $J=7.2\text{Hz}$).

Compound #24


15 **(±)-Trans-7-Amino-6-(2-amino-phenylsulfanyl)-8,8-diethyl-5,6,7,8-tetrahydro-naphthalen-2-ol**



20 ^1H NMR (400MHz) (CDCl_3 ; d; ppm): 7.44 (1H, m), 7.15 (1H, m), 6.84 (1H, m), 6.74 (1H, m), 6.70 (1H, m), 6.64 (1H, d), 6.57 (1H, m), 3.46 (1H, m), 3.07 (1H, d), 3.02 (1H, dd), 2.82 (1H, dd), 1.81 (2H, m), 1.73 (1H, m), 1.59 (1H, m), 0.71 (3H, t, $J=7.5\text{Hz}$), 0.65 (3H, t, $J=7.3\text{Hz}$).

Compound #25


(±)-Trans-7-hydroxy-1,1-dimethyl-trans-3-(2,2,2-trifluoro-ethylsulfanyl)-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium chloride



^1H NMR (400MHz) (CD_3OD ; d; ppm): 6.93 (1H, d), 6.80 (1H, d), 6.64 (1H, dd), 3.57 (2H, m), 3.40 (1H, d), 3.25-3.33 (2H, m), 3.00 (1H, dd), 1.53 (3H, s), 1.31 (3H, s).

Compound #26


(±)-Trans-3-(3-ethoxycarbonyl-propylsulfanyl)-7-hydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium chloride



^1H NMR (400MHz) (CDCl_3 ; d; ppm): 6.91 (1H, m), 6.80 (1H, m), 6.62 (1H, m), 4.14 (2H, m), 3.23 (1H, m), 3.14 (1H, m), 2.98 (1H, m), 2.77 (2H, m), 2.51 (2H, m), 1.96 (2H, m), 1.52 (3H, s), 1.30 (3H, s), 1.26 (3H, t, $J=7.1\text{Hz}$).

Compound #27


(±)-Trans-3-benzenesulfonylmethylsulfanyl-7-hydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium chloride



^1H NMR (400MHz) (CD_3OD ; d; ppm): 8.03 (2H, m), 7.80 (1H, m), 7.70 (2H, m), 6.88 (1H, d), 6.80 (1H, d), 6.64 (1H, dd), 4.56 (2H, s), 3.48 (2H, m), 3.21 (1H, m), 2.95 (1H, m), 1.53 (3H, s), 1.32 (3H, s).

5 **Compound #28**

(\pm)-Trans-7-hydroxy-1,1-dimethyl-trans-3-styrylsulfanyl-1,2,3,4-tetrahydronaphthalen-2-yl-ammonium chloride




10

^1H NMR (400MHz) (CD_3OD ; d; ppm): 7.39 (2H, m), 7.30 (2H, m), 7.23 (1H, m), 6.88 (1H, d), 6.78 (1H, s), 6.60 (2H, m), 6.34 (1H, m), 3.59 (2H, d), 3.38 (1H, m), 3.27 (1H, m), 3.16 (1H, m), 3.00 (1H, m), 1.51 (3H, s), 1.28 (3H, s).

15 **Compound #29**

(\pm)-Trans-7-hydroxy-TRANS-3-isobutylsulfanyl-1,1-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl-ammonium chloride




20

^1H NMR (400MHz) (CD_3OD ; d; ppm): 6.91 (1H, d), 6.79 (1H, d), 6.62 (1H, dd), 3.30 (1H, m), 3.23 (1H, dd), 3.10 (1H, m), 2.97 (1H, dd), 2.64 (2H, m), 1.88 (1H, m), 1.52 (3H, s), 1.29 (3H, s), 1.06 (6H).

Compound #30

(±)-Trans-7-hydroxy-1,1-dimethyl-trans-3-(2-phenoxy-ethylsulfanyl) -1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium chloride

5




¹H NMR (400MHz) (CD₃OD; d; ppm): 7.28 (2H, m), 6.89-6.97 (4H, m), 6.80 (1H, d),
6.63 (1H, dd), 4.27 (2H, m), 3.27-3.49 (3H, m), 3.15 (2H, m), 3.02 (1H, dd), 1.30 (3H, s),
10 1.26 (3H, s).

Compound #31

(±)-Trans-1,1-diethyl-7-hydroxy-trans-3-(2-phenoxy-ethylsulfanyl) -1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium chloride

15




¹H NMR (400MHz) (CD₃OD; d; ppm): 7.26 (2H, m), 6.91 (4H, m), 6.67 (2H, m), 4.27
(2H, m), 3.53 (1H, m), 3.45 (1H, m), 3.37 (1H, dd, J₁=5.3Hz, J₂=16.5Hz), 3.15 (2H, m),
2.93 (1H, dd, J₁=11.2Hz, J₂=16.0Hz), 2.08 (1H, m), 1.75 (2H, m), 1.66 (1H, m), 0.81 (3H,
20 t, J=7.3Hz), 0.69 (3H, t, J=7.0Hz).

Compound #34

(±)-Trans-7-amino-6-(4-bromo-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydronaphthalen-2-ol hydrochloride


5



^1H NMR (400 MHz) (CD_3OD ; d; ppm) : 7.54(m, 4H), 6.8(m, 2H), 6.6(m, 1H), 3.57(m, 1H), 3.40(d, 1H, $J=12\text{Hz}$), 3.14(dd, 1H, $J=5.3\text{Hz}$, $J=16\text{Hz}$), 2.86(dd, 1H, $J=11\text{Hz}$, 5Hz), 1.53(s, 3H), 1.32(s, 3H).


10

Compound #35 (±)-Trans-7-amino-8,8-dimethyl-6-(naphthalen-2-ylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol



15 ^1H NMR (400 MHz) (DMSO ; d; ppm) : 9.10(s, 1H), 8.04(d, 1H, $J=1.3\text{Hz}$), 7.88(m, 3H), 7.59(dd, 1H, $J=1.8\text{Hz}$, $J=3\text{Hz}$), 7.50(m, 2H), 6.7(m, 2H), 6.45(m, 1H), 3.57(1H), 3.00(1H), 2.72(m, 2H), 1.98(br, 2H), 1.33(s, 3H), 1.13(s, 3H).


Compound #36 (±)-Trans-7-amino-6-(4-hydroxyphenylsulfanyl)-8,8-diamino-5,6,7,8-tetrahydro-naphthalen-2-ol hydrochloride



ClH

¹H NMR (400 MHz) (CD₃OD; d; ppm) : 7.49(m, 2H), 6.82(m, 4H), 6.58(m, 1H), 3.3(m, 2H), 3.05(dd, 1H, J=5Hz, J=8Hz), 2.75(dd, 1H, J=9Hz, J=5Hz), 1.49(s, 3H), 1.29(s, 3H).

Compound #37 (±)-Trans-7-amino-6-(4-amino-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol dihydrochloride




ClH

ClH

¹H NMR (400 MHz) (CD₃OD; d; ppm) : 7.75(m, 2H), 7.38(m, 2H), 6.81(m, 2H), 6.61(m, 1H), 3.61(m, 1H), 3.43(d, 1H, J=12Hz), 3.11(dd, 1H, J=11Hz, J=5.2Hz), 2.87(dd, 1H, J=11Hz, J=5Hz), 1.54(s, 3H), 1.34(s, 3H).


Compound #38(±)-Trans-7-amino-6-(3-hydroxy-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol;



5


^1H NMR (400 MHz) (CD_3OD ; d; ppm) : 7.21(m, 1H), 7.04(m, 2H), 6.81(m, 3H), 6.60(m, 1H), 3.56(m, 1H), 3.40(m, 1H), 3.14(dd, 1H, $J=6\text{Hz}$, $J=11\text{Hz}$), 2.86(dd, 1H, $J=11\text{Hz}$, $J=5\text{Hz}$), 1.52(s, 3H), 1.31(s, 3H).

10 **Compound #39 (±)-Trans-3-(3-Amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-propionic acid ethyl ester hydrochloride;**



15 ^1H NMR (400 MHz) (CD_3OD ; d; ppm) : 6.92(d, 1H, $J=8.4\text{Hz}$), 6.80(d, 1H, $J=2.3\text{Hz}$), 4.19(q, 2H, $J=7\text{Hz}$, $J=7\text{Hz}$), 3.42(d, 1H, $J=11\text{Hz}$), 3.28(m, 2H), 2.98(m, 3H), 2.73(m, 2H), 1.52(s, 3H), 1.30(m, 6H).

Compound #40 (±)-Trans-7-amino-8,8-dimethyl-6-phenethylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol hydrochloride;




5

^1H NMR (400 MHz) (CD_3OD ; d; ppm) : 7.29(m, 4H), 7.23(m, 1H), 6.88(m, 1H), 6.78(m, 1H), 6.61(m, 1H), 3.18(m, 2H), 3.06(m, 6H), 1.49(s, 3H), 1.27(s, 3H).

Compound #41 (±)-Trans-2-(3-amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-2-ylsulfanyl)-propionamide hydrochloride:

10




^1H NMR (400 MHz) (CD_3OD ; d; ppm) : 6.89(m, 1H), 6.82(m, 1H), 6.63(m, 1H), 3.45(m, 1H), 3.2(m, 3H), 2.85(m, 2H), 2.7(m, 1H), 2.55(m, 1H), 1.5(s, 3H), 1.3(s, 3H).

15


Compound #42 (±)-Trans-3-(3-amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-propionic acid trifluoroacetate:

5



^1H NMR (400 MHz) (CD_3OD ; d; ppm) : 6.9(m, 1H), 6.78(m, 1H), 6.62(m, 1H), 3.45(d, 1H, $J=11\text{Hz}$), 3.21(m, 2H), 2.98(m, 3H), 2.70(m, 2H), 1.53(s, 3H), 1.30(s, 3H).

10 **Compound #43 (±)-Trans-3-{2-[1-carbamoyl-2-(4-hydroxy-phenyl)-ethylcarbamoyl]-ethylsulfanyl}-7-hydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-yl-ammonium; chloride:**




15 ^1H NMR (400 MHz) (DMSO ; d; ppm) : 9.2(br, 1H), 8.0(br, 2H), 6.9(m, 1H), 6.8(m, 1H), 6.65(m, 2H), 6.6(m, 1H), 6.5(m, 2H), 3.3-2.8(m, 11H), 1.45(s, 3H), 1.3(s, 1H).

Compound #44

3-trans-(2-ethoxycarbonyl-ethylsulfanyl)-1,1-diethyl-7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl-ammonium; chloride:

5




10

NMR(¹H, MeOD) : δ = 6.95(m, 1H), 6.7(m, 1H), 6.6(m, 1H), 4.2(m, 2H), 3.2(m, 2H), 2.95(m, 2H), 2.85(m, 1H), 2.65(m, 2H), 1.95(m, 1H), 1.8(m, 2H), 1.65(m, 1H), 1.3(m, 3H), 0.75(m, 3H), 0.65(m, 3H) ppm.

Compound #45

3-trans-(2-carboxy-ethylsulfanyl)-1,1-diethyl-7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl-ammonium; chloride



15

¹H NMR (CD₃OD) δ 6.98 (d, 1H, J 8Hz), 6.67-6.70 (m, 2H), 3.52 (d, 2H, J 11Hz), 3.27-3.41 (m, 3H), , 2.92-2.99 (m, 2H), 2.67-2.75 (m, 2H), 2.10-2.16 (m, 1H), 1.62-1.79 (m, 3H), 0.83 (m, 3H, J 8Hz), 0.72 (m, 3H, J 8Hz)

20

BIOLOGICAL ASSAYS

A. Receptor Affinity - Radioligand Binding Assay

5

Affinity for μ opioid receptor was assessed in vitro using radioligand binding assay employing rat brain membrane preparations as described in Schiller et al., Biophys. Res. Commun., 85, p.1322 (1975) incorporated herein by reference. Male Sprague-Dawley rats weighing between 350-450g were sacrificed by inhalation of CO₂. The rats were
10 decapitated and the brains minus cerebellum were removed and place in ice-cold saline solution and then homogenized in ice-cold 50 mM Tris buffer pH 7.4 (10ml/brain). The membranes were centrifuged at 14000 rpm for 30 min. at 4°C. The pellets were re-suspended in approximately 6ml/brain of ice-cold Tris buffer 50mM pH 7.4 and stored at -78°C until ready for use. Protein quantification of the brain homogenate was conducted
15 according to protein assay kit purchased (Bio-Rad).

(3H)- DAMGO was used as radioligands for the μ receptor. Radioligand 50 μ l, membranes 100 μ l and serially diluted test compound were incubated for 1 hr at room temperature or 22°C. Non specific binding was determined using 500 fold in the presence
20 of tracer and membranes. Free ligand was separated from bound by filtration through Whatman GF/B paper (presoaked in polyethylenimine 1% aqueous solution) and rinsing with ice-cold 50mM Tris pH 7.4 using a Brandel cell harvester. The filters were dried and radioactivity was counted in a 24 well microplate in the presence of 500 μ l scintillant per well. Radioactivity was measured using a Wallac 1450 Microbeta counter. Inhibition
25 constants (K_i) for the various compounds were determined from the IC₅₀ according to the Cheng and Prusoff equation.

B. Central and Peripheral Analgesia - PBQ Writhing Assay

PBQ (phenyl-p-benzoquinone) induced writhing in mice was used to assess both central
5 and peripheral analgesia of compounds of the invention according to the experimental
protocol described in Sigmund et al., Proc. Soc. Exp. Biol. Med., 95, p. 729(1957) which is
incorporated herein by reference. The test was performed on CD-1 male mice weighing
between 18 and 22g. The mice were weighed and marked and administered peritoneally
with 0.3ml/20g by weight 0.02% solution of phenylbenzoquinone (PBQ) . The number of
10 writhings was counting 5 minutes after PBQ injection and for a period of 20 minutes.
ED50 values (dose of compound which induced a 50% reduction in the number of writhes
observed compared to the control) was calculated using non linear regression of dose
response curve. The PBQ was injected at time intervals of 5, 20 or 30 minutes after
intravenous, subcutaneous or oral administration respectively of the compound (or
15 medium, or standard).

Aqueous solution of 0.02% PBQ was prepared by dissolving PBQ in 5% ethanol/saline
0.9% solution.


20 C. Central analgesia tail flick assay

The compounds of the present invention were evaluated for central analgesia as described
in D'Amour et al. J.Pharmacol. 72:74-79, 1941 which is herein incorporated by reference.
Male mice CD-1 were weighed and marked on their tail. Tail is placed between two light
25 beams at specific intensity using a Tail Flick Analgesia Meter, Columbus Instrument. Each
mouse was tested at specific time points after compound or saline injection and latency
period was noted. Cut off latency was settled at 10 seconds. ED₅₀ value was calculated
from results obtained for different doses at 5 minutes for intravenous injection and at 30
minutes for oral and subcutaneous injection using non linear regression analysis of the dose
30 response curve.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses or adaptations of the invention following, in general, the principles of the invention and including such departures from the present description as
s come within known or customary practice within the art to which the invention pertains, and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

CLAIMS

1. A compound represented by formula (I)



and pharmaceutically acceptable derivative thereof;

wherein;

Z is S, SO or SO₂,

X is selected from anyone of

(i) a bond;

(ii) -CR₇R₈- wherein R₇ and R₈ are independently selected from the group consisting of H, OH, halogen, CN, COOH, CONH₂, amino, nitro, SH, C₁₋₆ alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkynyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N; and COOR_c wherein R_c is C₁₋₆alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl; R₇ and R₈ can also be connected to form C₃₋₈ cycloalkyl, a C₃₋₈ cycloalkenyl or a saturated heterocycle of from 3 to 8 atoms;

R₁ is selected from the group consisting of H, C₁₋₁₂alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₁₂alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₁₂alkynyl where one or more of the carbon atoms may optionally be

substituted by one or more heteroatoms selected from O, S and N, C₆₋₁₂ aryl, C₆₋₁₂ aralkyl, C₆₋₁₂ aryloxy, C₁₋₁₂ acyl, heteroaryl having from 6 to 12 atoms, and phosphoryl;

5 **R₂ and R₃** are independently selected from the group consisting of C₁₋₆ alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkynyl where one or more of the carbon atoms
10 may optionally be substituted by one or more heteroatoms selected from O, S and N, C₆₋₁₂ aryl, C₆₋₁₂ aralkyl, heteroaryl having from 6 to 12 atoms, and H; *or*

R₂ and R₃ may together form a saturated heterocycle of from 3 to 8 atoms;

15 **R₄ and R₅** are independently selected from the group consisting of C₁₋₆ alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkynyl where one or more of the carbon atoms
20 may optionally be substituted by one or more heteroatoms selected from O, S and N, and H;

R₄ and R₅ can also be connected to form C₃₋₈ cycloalkyl, a C₃₋₈ cycloalkenyl or a saturated heterocycle of from 3 to 8 atoms;

25 **R₆** is hydrogen, OH, C₁₋₆ alkyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, C₂₋₆alkynyl where one or more of the carbon atoms may optionally be substituted by one or
30 more heteroatoms selected from O, S and N, O-C₁₋₆ alkyl where one or more of

the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, O-C₂₋₆alkenyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, O-C₂₋₆alkynyl where one or more of the carbon atoms may optionally be substituted by one or more heteroatoms selected from O, S and N, halogen, CN, COOH, CONH₂, amino, nitro, or SH;

with the provisos that:

- 1) not both R₄ and R₅ are H; and
 - 2) at least one of R₂ and R₃ is H or C₁₋₆ alkyl.
2. The compound of claim 1 wherein Z is S and X is -CH₂-.
 3. The compound of claim 2 wherein the geometric relation between the substituents of carbons marked by an * is *trans*.
 4. The compound of claim 3 wherein R₂ and R₃ are H.
 5. The compound of claim 3 wherein R₆ is H.
 6. The compound of claim 5 wherein R₄ and R₅ are C₁₋₄ alkyl.
 7. The compound of claim 5 wherein R₄ and R₅ are independently selected from the group consisting of methyl, ethyl, isopropyl, propyl, butyl, and isobutyl.
 8. The compound of claim 5 wherein R₄ and R₅ are ethyl.
 9. The compound of claim 5 wherein R₄ and R₅ are methyl.

10. The compound of claim 5 wherein R_1 is selected from the group consisting of H, C_{1-12} alkyl, C_{6-12} aryl, and C_{6-12} aralkyl.


11. The compound of claim 5 wherein R_1 is selected from the group consisting of C_{1-6} alkyl, C_{6-12} aryl, and C_{6-12} aralkyl.

12. The compound of claim 5 wherein R_1 is C_{1-6} alkyl.

13. The compound of claim 5 wherein R_1 is selected from the group consisting of CH_3 , $-(CH_2)_n-CH_3$, and $-(CH_2)_n-O-CH_3$ wherein n is an integer selected between 1 and 5.

14. The compound of claim 5 wherein R_1 is C_{6-12} aryl.

15. The compound of claim 14 wherein R_1 is selected from the group consisting of



wherein A is selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkyl, C_{2-6} alkenyl,

C_{2-6} alkynyl, O- C_{1-6} alkyl, O- C_{2-6} alkenyl, O- C_{2-6} alkynyl, , S- C_{1-6} alkyl, S- C_{2-6} alkenyl,


S- C_{2-6} alkynyl, N- C_{1-6} alkyl, N- C_{2-6} alkenyl, N- C_{2-6} alkynyl, CF_3 , fluoro, chloro, bromo, iodo,

OH, SH, CN, nitro, amino, aminoamidino, amidino, guanido, COOH, and COOR_z

wherein R_z is C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl.

16. The compound of claim 5 wherein R_1 is C_{6-12} aralkyl.

17. The compound of claim 5 wherein R_1 is selected from the group consisting of



5 wherein A is selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkenyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $O-C_{1-6}$ alkyl, $O-C_{2-6}$ alkenyl, $O-C_{2-6}$ alkynyl, , $S-C_{1-6}$ alkyl, $S-C_{2-6}$ alkenyl, $S-C_{2-6}$ alkynyl, $N-C_{1-6}$ alkyl, $N-C_{2-6}$ alkenyl, $N-C_{2-6}$ alkynyl, CF_3 , fluoro, chloro, bromo, iodo, OH, SH, CN, nitro, amino, aminoamidino, amidino, guanido, $COOH$, and $COOR_z$ wherein R_z is C_{1-6} alkyl, C_{1-6} alkenyl or C_{1-6} alkynyl and Y is $-(CH_2)_m-$ wherein m is an
10 integer selected between 1 and 5.

18. The compound of claim 1 wherein said compound selected from the group consisting of: **Trans-7-Amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol, (compound #1);** **Trans and cis-7-Amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-**
15 **dihydro-naphthalen-2-ol, (compound #2);** **Trans-7-Amino-8,8-diethyl-6-methylsulfanyl-5,6,7,8-dihydro-naphthalen-2-ol, (compound #3);** **Trans-7-Amino-8,8-dimethyl-6-phenylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol (compound #4);** **Trans-7-Amino-8,8-dimethyl-6-(pyridin-2-ylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol**
Compound #5;
20 **Trans-7-Amino-8,8-dimethyl-6-(pyrimidin-2-ylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol**
Compound #6;
Trans-7-Amino-6-(3-amino-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol
Compound #7;
Trans-7-Amino-8,8-dimethyl-6-(4-methylsulfanyl-phenylsulfanyl)-5,6,7,8-tetrahydro-
25 **naphthalen-2-ol Compound #8;**
Trans-7-Amino-6-benzenesulfonylmethylsulfanyl-8,8-diethyl-5,6,7,8-tetrahydro-
naphthalen-2-ol Compound #9;

- Trans-2-(3-Amino-4,4-diethyl-6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-
acetamide **Compound #10**;
- Trans-(3-Amino-4,4-diethyl-6-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanylmethyl)-
phosphonic acid diethyl ester **Compound #11**;
- 5 Trans-7-Amino-8,8-diethyl-6-(2-hydroxy-ethylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol
Compound #12;
- Trans-7-Amino-6-(5-amino-2*H*-[1,2,4]triazol-3-ylsulfanyl)-8,8-diethyl-5,6,7,8-tetrahydro-
naphthalen-2-ol **Compound #13**;
- Trans-7-Amino-6-(2-amino-ethylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol
10 **Compound #14**;
- Trans-7-Amino-6-(5-amino-2*H*-[1,2,4]triazol-3-ylsulfanyl)-8,8-dimethyl-5,6,7,8-
tetrahydro-naphthalen-2-ol **Compound #15**;
- Trans-7-Amino-8,8-dimethyl-6-propylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol
Compound #16;
- 15 Trans-7-Amino-6-isopropylsulfanyl-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol
Compound #17;
- Trans-7-Amino-6-(2-hydroxy-ethylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-
ol **Compound #18**;
- Trans- 2-(3-Amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-
20 acetamide **Compound #19**;
- Trans-7-Dimethylamino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol
Compound #20;
- 8,8-dimethyl-trans-7-methylamino-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol
Compound #21;
- 25 Trans-7-Amino-8,8-diethyl-6-phenylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol
Compound #22;
- 8,8-dimethyl-trans-6-phenylsulfanyl-7-propylamino-5,6,7,8-tetrahydro-naphthalen-2-ol
Compound #23;
- Trans-7-Amino-6-(2-amino-phenylsulfanyl)-8,8-diethyl-5,6,7,8-tetrahydro-naphthalen-2-ol
30 **Compound #24**;

- Trans-7-Amino-8,8-dimethyl-6-(2,2,2-trifluoro-ethylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #25**;
- Trans-4-(3-Amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-butyric acid ethyl ester **Compound #26**;
- 5 Trans-7-Amino-6-benzenesulfonylmethylsulfanyl-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #27**;
- Trans-7-Amino-8,8-dimethyl-6-(3-phenyl-allylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #28**;
- Trans-7-Amino-6-isobutylsulfanyl-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol
- 10 **Compound #29**;
- Trans-7-Amino-8,8-dimethyl-6-(2-phenoxy-ethylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #30**;
- Trans-7-Amino-8,8-diethyl-6-(2-phenoxy-ethylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #31**;
- 15 (-)Trans-7-amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #32**; (+)Trans-7-amino-8,8-dimethyl-6-methylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #33**; Trans-7-amino-6-(4-bromo-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydronaphthalen-2-ol **Compound #34**;
- Trans-7-amino-8,8-dimethyl-6-(naphthalen-2-ylsulfanyl)-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #35**; Trans-7-Amino-6-(4-hydroxy-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #36**; Trans-7-amino-6-(4-amino-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #37**; Trans-7-amino-6-(3-hydroxy-phenylsulfanyl)-8,8-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #38**; Trans-3-(3-Amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-propionic acid ethyl ester **Compound #39**; Trans-7-amino-8,8-dimethyl-6-phenethylsulfanyl-5,6,7,8-tetrahydro-naphthalen-2-ol **Compound #40**; Trans-2-(3-amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-2-ylsulfanyl)-propionamide **Compound #41**; Trans-3-(3-amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-propionic acid
- 20
- 25

Compound #42; Trans-2-[3-(3-Amino-6-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydro-naphthalen-2-ylsulfanyl)-propionylamino]-3-(4-hydroxy-phenyl)-propionamide

Compound #43;

3-trans-(2-ethoxycarbonyl-ethylsulfanyl)-1,1-diethyl-7-hydroxy-1,2,3,4-tetrahydro-

5 naphthalen-2-yl **Compound #44;**

3-trans-(2-carboxy-ethylsulfanyl)-1,1-diethyl-7-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl

Compound #45;

and pharmaceutically acceptable derivatives thereof.

10

19. The compound of claim 18 wherein said compound is selected from the group consisting of **compound#1, compound#3, compound#4, compound#5, compound#9, compound#11, compound#15, compound#31, compound#36, compound#37, compound#39 compound#41, compound#43, compound#44 and**
15 **compound#45.**

20

20. The compound of claim 19 wherein said compound is selected from the group consisting of **compound#1, compound#3, compound#5, compound#36, compound#44 and compound#45.**

25

21. The compound of claim 19 wherein said compound is selected from the group consisting of **compound#32 and compound#33.**

22. A compound according to any one of claims 1 to 20 wherein said compound is in the
25 form of the (+) enantiomer, the (-) enantiomer and mixture of the (+) and (-) enantiomer including racemic mixture.

23. A compound according to any one of claims 1 to 20 wherein said compound is in the
30 form of the (+) enantiomer.

24. A compound according to any one of claims 1 to 20 wherein said compound is in the form of the (-) enantiomer.

25. A compound according to any one of claims 1 to claim 24 for use in therapy.

5

26. A method of treating pain in a mammal comprising administering to said mammal an analgesic amount of a compound as defined in any one of claims 1 to 24.

27. A pharmaceutical composition comprising a compound as defined in any one of claims
10 1 to 24 and pharmaceutically acceptable carriers, diluents or adjuvants.

28. Use of a compound according to any one of claims 1-24, for the manufacture of a medicament for the treatment of pain.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/02401

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07C 323/10, C07D 249/10, C07D 239/32, C07D 213/62, A61K 31/095,
A61K 31/4196, A61K 31/505, A61K 31/4402, A61P 25/04, A61P 29/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07C, C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1377356 A (EISAI CO., LTD), 11 December 1974 (11.12.74) --	1-28
X	STN International, File CAPLUS, CAPLUS, accession no. 1973:546294, document no. 79:146294, Tanabe Seiyaku Co., Ltd.: "1,1-Dimethyl-2-dimethylamino-7-hydroxy- 1,2,3,4-tetrahydronaphthalene"; & JP,A2,48057962, 19730814 --	1-28

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

23 March 2000

Date of mailing of the international search report

25-04-2000

Name and mailing address of the ISA/

Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell/mj

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/02401

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN International, File CAPLUS, CAPLUS accession no. 1976:542882, document no. 85:142882, Hirose, Noriyasu et al: "Synthesis and analgesic activities of some 2-amino-1,1- dialkyl-7-methoxy-1,2,3,4-tetrahydronaphthalenes and related compounds"; & Yakugaku Zasshi (1976), 96(2), 185-94 --	1-28
X	Chemical Abstracts, Volume 84, No 7, 16 February 1976 (16.02.76), (Columbus, Ohio, USA), page 44, THE ABSTRACT No 43700e, JP, 7537764 A, (Hirose, Norjyasu et al) 8 April 1975 (08.04.75) --	1-28
A	STN International, File CAPLUS, CAPLUS accession no. 1988:87584, document no. 108:87584, Krotowska, Anna et al: "Dopamine D2-receptor affinities of resolved C1-dimethylated 2-aminotetralins"; & Acta Pharm. Suec. (1987), 24(4) 145-52 --	1-28
A	STN International, File CAPLUS, CAPLUS accession no. 1984:454672, document no. 101:54672, Hacksell, Uli et al: "C1-Methylated 5-hydroxy-2(dipropylamino)teatralins: central dopamine-receptor stimulating activity"; & J. Med. Chem. (1984), 27(8), 1003-7 --	1-28
A	WO 9504028 A1 (SMITHKLINE BEECHAM PLC), 9 February 1995 (09.02.95) --	1-28
A	WO 9716422 A1 (ALLERGAN), 9 May 1997 (09.05.97) --	1-28
A	US 5545755 A (CHIU-HONG LIN ET AL), 13 August 1996 (13.08.96) --	1-28

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/02401

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9109006 A1 (AKTIEBOLAGET ASTRA), 27 June 1991 (27.06.91) -- -----	1-28

INTERNATIONAL SEARCH REPORT

Search request No.
PCT/SE99/02401

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international-type search report has not been established in respect of certain claims for the following reasons:

1. ☒ Claims No.: 26
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 26 relates to a method of treatment of the human or animal body by surgery or by therapy/Rule 39.1 (iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds/compositions.
2. ☐ Claims No.:
because they relate to parts of the national application that do not comply with the prescribed requirements to such an extent that no meaningful international-type search can be carried out, specifically:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international-type search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international-type search report covers only those claims for which fees were paid, specifically claims No.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international-type search report is restricted to the invention first mentioned in the claims, it is covered by claims No.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/12/99

International application No.

PCT/SE 99/02401

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1377356 A	11/12/74	CH 589600 A	15/07/77
		DE 2340629 A	21/03/74
		FR 2196158 A,B	15/03/74
		JP 49054353 A	27/05/74
		JP 51024508 B	24/07/76

WO 9504028 A1	09/02/95	AU 7532094 A	28/02/95
		EP 0711272 A	15/05/96
		JP 9500879 T	28/01/97
		US 5773463 A	30/06/98
		ZA 9405504 A	26/01/96

WO 9716422 A1	09/05/97	AU 7598596 A	22/05/97
		US 5672710 A	30/09/97

US 5545755 A	13/08/96	JP 6502165 T	10/03/94
		AU 8752591 A	20/05/92
		CA 2090321 A	13/04/92
		EP 0552246 A	28/07/93
		HU 211928 B	29/01/96
		HU 9500417 A	29/01/96
		WO 9206967 A	30/04/92
		AU 654653 B	17/11/94
		DE 69032725 D,T	08/04/99
		EP 0476016 A,B	25/03/92
		SE 0476016 T3	
		FI 915656 D	00/00/00
		NO 176437 B,C	27/12/94
		RU 2086535 C	10/08/97
		AT 172712 T	15/11/98
		AU 5822190 A	07/01/91
		CA 2051399 A	01/12/90
		ES 2123500 T	16/01/99
		JP 2785879 B	13/08/98
		JP 4505618 T	01/10/92
		WO 9015047 A	13/12/90

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

02/12/99

PCT/SE 99/02401

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9109006 A1	27/06/91	AT 137490 T	15/05/96
		AU 639742 B	05/08/93
		AU 6958791 A	18/07/91
		CA 2046292 A	08/06/91
		DE 69026816 D,T	02/10/96
		DK 457883 T	26/08/96
		EP 0457883 A,B	27/11/91
		SE 0457883 T3	
		ES 2086528 T	01/07/96
		FI 913713 D	00/00/00
		GR 3020122 T	31/08/96
		JP 4503819 T	09/07/92
		LT 1733 A	25/08/95
		LT 4035 B	25/09/96
		LV 10607 A,B	20/04/95
		NO 176018 B,C	10/10/94
		NO 177901 B,C	04/09/95
		NO 940861 A	02/08/91
		RU 2086537 C	10/08/97
		SE 8904127 D	00/00/00
		US 5376687 A	27/12/94
